All clinical trial information provided by Daiichi Sankyo on this site and on other clinical trial registries sites, such as the US ClinicalTrials.gov, EU CTIS/EU CTR, Japan jRCT, etc. are meant to ensure transparency regarding the clinical trials and is not intended to promote or commercialize Daiichi Sankyo’s medicines.
Please note that the results of each clinical trial shown are based on findings available at the completion of the trial and may not represent the most comprehensive or up-to-date information.
For detailed information about approved uses of medications, please refer to the official package inserts. The information on our site and linked sources are not a substitute for a doctor's advice. If you have any questions, please consult your doctor.

Search Clinical Trial


Study Title
Conditions		 Daiichi Sankyo
Study ID
Registory ID		 Results
Lay Summaries
A Phase 1, Multicenter, Open-label, First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors

Conditions: Advanced Solid Tumor/Metastatic Solid Tumor/Unresectable Solid Tumor		 DS1025-103
NCT07681882
A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)

Conditions: Hormone Receptor Positive Breast Cancer/HER2-low or HER2-ultralow Breast Cancer/Unresectable or Metastatic Breast Cancer		 U31402-287
NCT07701941
Single ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of DS2001a in healthy participants

Conditions: Healthy Participants		 DS2001-057
jRCT2031250859
A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)

Conditions: HER2+/HR+ Metastatic Breast Cancer		 DS8201-0004-CIS-MA
NCT07683754
Medical Access Program for Ifinatamab Deruxtecan

Conditions: Small-cell Lung Cancer		 DS7300-0001-EAP-MA
NCT07535359
A Phase 1, Multicenter, Open-label, First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors

Conditions: Advanced Solid Tumor/Metastatic Solid Tumor/Unresectable Solid Tumor		 DS1025-103
NCT07681882
A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors

Conditions: Advanced Solid Tumor		 DS1103-074
NCT05765851
A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS3610a in Participants With Advanced Solid Tumor

Conditions: Solid Tumors/Metastatic Solid Tumors		 DS3610-071
NCT07159126
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies

Conditions: Hematological Malignancies/B-cell Non-Hodgkin Lymphoma 		DS3790-076
NCT07220616
A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS5361b in Participants With Advanced Solid Tumors

Conditions: Advanced Solid Tumor 		DS5361-061
NCT07182591
A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)

Conditions: Advanced or Metastatic Adrenocortical Carcinoma/Metastatic Castration-resistant Prostate Cancer 		DS9051-079
NCT07189403
A Phase 1, Multicenter, First-in-human Study of DS-1471a In Subjects With Advanced Solid Tumors

Conditions: Advanced or Metastatic Solid Tumors 		DS1471-079
NCT06074705		 Results
A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Conditions: Netherton Syndrome 		DS2325-119
NCT05979831		 Results
Lay Summaries
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals With PseudoXanthoma Elasticu

Conditions: Pseudoxanthoma Elasticum 		DS1211-A-U201
NCT05569252		 Results
Lay Summaries
A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus 		DS7011-107
NCT05638802		 Results
Lay Summaries
DS-7830a Phase 1 Study－A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Administration of DS-7830a in Japanese Healthy Adults, and to Evaluate the Effect of Food (High-fat and Low-fat Meal) on the Pharmacokinetics of Orally Administrated DS-7830a in Japanese Healthy Adults－

Conditions: Healthy Participants 		DS7830-131
jRCT2051230152		 Results
Phase 1, Open-Label, Multicenter, First-In-Human Trial of Ds-2243a in Participants With Advanced Solid Tumors

Conditions: Sarcoma/Solid Tumors 		DS2243-054
NCT06644755
Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors

Conditions: Advanced Solid Tumor/Metastatic Solid Tumor 		DS3939-077
NCT05875168
A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)

Conditions: Ovarian Cancer/Germ Cell Tumor/Advanced Solid Tumors 		DS9606-137
NCT05394675
A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

Conditions: Advanced Solid Tumor/Metastatic Solid Tumors 		DS6000-126
NCT06660654
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian01)

Conditions: Solid Cancer 		DS6000-109
NCT06161025
Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Conditions: Renal Cancer/Ovarian Cancer 		DS6000-A-U101
NCT04707248
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Conditions: Esophageal Squamous Cell Carcinoma 		DS7300-202
NCT06644781
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)

Conditions: Small-cell Lung Cancer 		DS7300-189
NCT06362252
A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Conditions: Recurrent or Metastatic Solid Tumors 		DS7300-203
NCT06330064
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

Conditions: Small-cell Lung Cancer 		DS7300-188
NCT06203210
A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

Conditions: Small-cell Lung Cancer 		DS7300-127
NCT05280470
Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)

Conditions: Advanced Solid Cancer 		DS7300-A-J101
NCT04145622
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment (TROPION-Urothelial03)

Conditions: Urothelial Cancer/Bladder Cancer 		DS1062-328
NCT07129993
Medical Access Program for Datopotamab Deruxtecan

Conditions: Advanced Non-small Cell Lung Cancer/Metastatic Non-small Cell Lung Cancer 		DS1062-0003-EAP-MA
NCT06279728
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

Conditions: Non-small Cell Lung Cancer 		DS1062-A-U304
NCT05215340
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

Conditions: Non-small Cell Lung Cancer 		DS1062-A-U303
NCT05555732
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)

Conditions: Non-small Cell Lung Cancer 		DS1062-A-U301
NCT04656652		 Results
Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05)

Conditions: Non-small Cell Lung Cancer 		DS1062-A-U202
NCT04484142		 Results
Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Conditions: Non-small Cell Lung Cancer 		DS1062-A-U102
NCT04526691
Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)

Conditions: Solid Cancer/Non-Small-Cell Lung Cancer/Triple Negative Breast Cancer 		DS1062-A-J101
NCT03401385
A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors (HERTHENA-PanTumor01)

Conditions: Advanced Solid Tumor/Melanoma/Head and Neck Cancer/Gastric Cancer 		U31402-277
NCT06172478
Medical Access Program for Patritumab Deruxtecan

Conditions: Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer 		U31402-0001-EAP-MA
NCT06099639
A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)

Conditions: Non-small Cell Lung Cancer		 U31402-A-U301
NCT05338970
A Multi-Center, Open-Label, Phase 2 Study to Evaluate Safety and Efficacy of U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer (CRC)

Conditions: Colorectal Cancer 		U31402-A-U202
NCT04479436		 Results
Lay Summaries
A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) (HERTHENA-Lung01)

Conditions: Non-small Cell Lung Cancer 		U31402-A-U201
NCT04619004		 Results
A Phase 1 Open-Label Study of HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

Conditions: Non-small Cell Lung Cancer 		U31402-A-U103
NCT04676477
A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer 		U31402-A-U102
NCT03260491
Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer

Conditions: Breast Cancer 		U31402-A-J101
NCT02980341		 Results
Lay Summaries
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02)

Conditions: Endometrial Cancer 		DS8201-854
NCT07022483
A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Conditions: Recurrent or Metastatic Solid Tumors 		DS8201-801
NCT07015697
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Conditions: Non-small Cell Lung Cancer 		DS8201-793
NCT06899126
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Conditions: Ovarian Cancer 		DS8201-772
NCT06819007
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China: A Nation-wide, Multi-center, Prospective, Non-interventional Study

Conditions: HER2-positive Gastric Cancer/HER2-positive Gastroesophageal Junction Cancer 		DS8201-0076-NIS-MA
NCT06846996
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients With HER2 Mutant Metastatic Non-small Cell Lung Cancer: a Prospective, Observational Study (RERUN)

Conditions: Non-small Cell Lung Cancer 		DS8201-0079-NIS-MA
NCT06809764
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

Conditions: Gastric Cancer/Gastroesophageal Junction Cancer 		DS8201-724
NCT06731478
A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Conditions: Breast Cancer 		SCN-EHT-NIS-BC002
NCT06210776
A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Conditions: Advanced Cancer/Metastatic Cancer 		ROMast-001
NCT06174987
A Prospective Non-interventional Study (NIS) of Trastuzumab DeRuxtecan (T-DXd) for Adult Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction (GEJ) AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen, Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies in a Real-world Setting in Europe (PROSPERITY)

Conditions: HER2-positive Advanced Gastric Cancer;
HER2-positive Gastroesophageal Junction Adenocarcinoma 		DS8201-0007-NIS-MA
NCT05993234
A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-(Ultra)Low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy

Conditions: Breast Cancer 		DS8201-0005-NIS-MA
NCT05945732
A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

Conditions: Breast Cancer 		DS8201-0001-CIS-MA
NCT05950945
Multicenter, Open-label Expanded Access Program of Trastuzumab Deruxtecan in Subjects With HER2 Mutated Metastatic/Locally-advanced Non-small Cell Lung Cancer (NSCLC)

Conditions: Non-small Cell Lung Cancer 		ENH-DS-22004
jRCT2071220096		 Results
A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)

Conditions: Colorectal Cancer 		DS8201-A-U207
NCT04744831		 Results
Lay Summaries
A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 		DS8201-A-U306
NCT04704934
A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-Lung02)

Conditions: Non-small Cell Lung Cancer 		DS8201-A-U206
NCT04644237		 Results
Lay Summaries
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)

Conditions: Breast Cancer 		DS8201-A-U305
NCT04622319		 Results
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)

Conditions: Breast Cancer/Non-small Cell Lung Cancer 		DS8201-A-U106
NCT04042701
A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)

Conditions: Gastric Cancer 		DS8201-A-U205
NCT04014075		 Results
Lay Summaries
A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects (DESTINY-Breast04)

Conditions: Breast Cancer 		DS8201-A-U303
NCT03734029		 Results
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane (DESTINY-Breast03)

Conditions: Breast Cancer 		DS8201-A-U302
NCT03529110		 Results
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast02)

Conditions: Breast Cancer 		DS8201-A-U301
NCT03523585		 Results
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer

Conditions: Breast Cancer/Urothelial Cancer 		DS8201-A-U105
NCT03523572		 Results
Lay Summaries
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC) (DESTINY-Lung01)

Conditions: Non-small Cell Lung Cancer 		DS8201-A-U204
NCT03505710		 Results
Lay Summaries
A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Colorectal Cancer (DESTINY-CRC01)

Conditions: Colorectal Cancer 		DS8201-A-J203
NCT03384940		 Results
A Phase 1, Multicenter, Open-label, Single Sequence Crossover Study to Evaluate Drug-drug Interaction Potential of OATP1B/CYP3A Inhibitor on the Pharmacokinetics of DS-8201a in Subjects With HER2-expressing Advanced Solid Malignant Tumors

Conditions: Neoplasm Metastasis 		DS8201-A-A104
NCT03383692		 Results
Lay Summaries
Phase 1, Multicenter, Open-label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2-Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

Conditions: Gastric Cancer/Breast Cancer 		DS8201-A-A103
NCT03368196		 Results
Lay Summaries
Phase 1, Multicenter, Open-label, Multiple-dose Study of DS-8201a to Assess the Effect on the QT Interval and Pharmacokinetics in Subjects With HER2-expressing Metastatic and/or Unresectable Breast Cancer

Conditions: Breast Cancer 		DS8201-A-J102
NCT03366428		 Results
Lay Summaries
An Open-label, Multi-center, Expanded Access Study of Trastuzumab Deruxtecan in Japanese Subjects With HER2-positive Advanced Gastric or Gastroesophageal Junction Adeocarcinoma

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 		DS8201-C-J4001
jRCT2080225138		 Results
A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (DESTINY-Gastric01)

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 		DS8201-A-J202
NCT03329690		 Results
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)

Conditions: Breast Cancer 		DS8201-A-U201
NCT03248492		 Results
Lay Summaries
Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201a, in Subjects With Advanced Solid Malignant Tumors

Conditions: Advanced Solid Malignant Tumors 		DS8201-A-J101
NCT02564900		 Results
Lay Summaries
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan Through a Named Patient Program (EUROPA T-DXd)

Conditions: HER2-positive Breast Cancer 		DS8201-0002-EAP-MA
NCT05458401
A Multi-national, Non-interventional Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia

Conditions: Primary Hypercholesterolaemia/Mixed Dyslipidaemia 		DS-ASCAHQ-BMP-HC001
NCT07206472
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer in Selected Ex-US Countries

Conditions: Triple Negative Breast Cancer 		DS1062-0007-NIS-EPI
NCT07092254
Real-World Outcomes of Patients With HR-Positive HER2-Negative Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i in the United States

Conditions: Advanced/Metastatic HER2-negative Breast Cancer 		U31402-0012-NIS-MA
NCT06975371
Real-world Outcomes of Patients With HER2-positive (HER2+) Metastatic Breast Cancer (mBC) After Treatment With Trastuzumab Deruxtecan (T-DXd) in the United States

Conditions: HER2-positive Breast Cancer 		U31402-0010-NIS-MA
NCT06833268
A Clinical Study To investigate Incidence Rate of Seasonal Influenza

Conditions: Seasonal influenza 		DS5269-034
jRCT1030240609
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission

Conditions: Acute Myeloid Leukemia/Leukemia 		AC220-167
NCT06824168
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-WILD)

Conditions: Acute Myeloid Leukemia 		AC220-168
NCT06578247
A Phase 1, Open Label, Randomized, Parallel Drug Interaction Study to Evaluate the Effect of a CYP3A Weak Inducer Rufinamide on the Pharmacokinetics of Quizartinib in Healthy Subjects

Conditions: Healthy Participants 		AC220-164
NCT06740825
A Phase 1, Multicenter, Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Severe Impaired Hepatic Function

Conditions: Hepatic Impairment 		AC220-163
NCT06740799
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination With Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) With FLT3-ITD Mutations

Conditions: Acute Myeloid Leukemia 		AC220-A-U202
NCT03793478
A Study to Evaluate the Safety and Pharmacokinetics of Quizartinib in Combination With Standard Induction Therapy and Consolidation Therapy in Chinese Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia 		AC220-A-A103
NCT03723681
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)

Conditions: Acute Myeloid Leukemia/Leukemia 		AC220-A-U302
NCT02668653		 Results
Lay Summaries
Phase 2 Open-label, Single-arm Study of Quizartinib (AC220) Monotherapy in Japanese Patients With FLT3-ITD Positive Refractory or Relapsed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia		 AC220-A-J201
NCT02984995		 Results
Lay Summaries
Phase 1b, Open-label, Dose Escalation Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia 		AC220-A-J102
NCT02834390		 Results
Lay Summaries
A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Relapsed or Refactory Acute Myeloid Leukemia 		AC220-A-J101
NCT02675478		 Results
Lay Summaries
A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Conditions: Acute Myeloid Leukemia 		AC220-007
NCT02039726		 Results
Lay Summaries
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia 		2689-CL-2004
NCT01565668		 Results
Lay Summaries
A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant

Conditions: Acute Myeloid Leukemia		 2689-CL-0011
NCT01468467		 Lay Summaries
A Phase 1 Study of AC220 (ASP2689) in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia		 2689-CL-0005
NCT01390337		 Lay Summaries
A Phase 1 Open-Label, Dose Finding, Safety and Tolerability Study of AC220 Administered Daily to Patients With Advanced Solid Tumors

Conditions: Solid Cancer 		AC220-004
NCT01049893		 Lay Summaries
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations

Conditions: Acute Myeloid Leukemia 		AC220-002
NCT00989261		 Results
Lay Summaries
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions

Conditions: Acute Myeloid Leukemia 		CP0001
NCT00462761		 Results
Lay Summaries
A Single Blind, Fixed Sequence, Single-dose Study to Evaluate the Serious Risk of QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

Conditions: Healthy Participants 		AC220-165
NCT06772246
An Open Label Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

Conditions: Healthy Participants 		AC220-A-U107
NCT04796831		 Results
Lay Summaries
An Open-label, Parallel Drug Interaction Study to Evaluate the Effect of a CYP3A Moderate Inducer Efavirenz on the Pharmacokinetics of Quizartinib in Healthy Subjects

Conditions: Healthy Participants 		AC220-A-U106
NCT04459598		 Results
An Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Moderate Impaired Hepatic Function as Defined by NCI-ODWG Criteria

Conditions: Moderate Hepatic Impairment		 AC220-A-U105
NCT04473664		 Results
A Phase 1, Open-Label, Fixed Sequence Drug Interaction Study to Evaluate the Potential Intestinal Inhibitory Effect of Quizartinib on the Pharmacokinetics of a Pgp Substrate Dabigatran Etexilate in Healthy Subjects

Conditions: Healthy Participants 		AC220-A-U104
NCT04459585		 Results
A Phase 1, Open-label, Single-dose, Parallelgroup Study to Evaluate the Pharmacokinetics of Quizartinib and its Active Metabolite, AC886, in Subjects with Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Conditions: Liver Disease/Healthy Participants 		AC220-016 Lay Summaries
A phase 1, open-label, randomized, placebo controlled, parallel group study to evaluate the effect of ketoconazole and fluconazole on the pharmacokinetics of quizartinib and its active metabolite, AC886, in healthy volunteers

Conditions: Healthy Participants 		AC220-015 Lay Summaries
A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group, Relative Bioavailability Study of Two AC220 Formulations in Healthy Volunteers

Conditions: Healthy Participants 		AC220-014 Lay Summaries
A Phase 1, Open-Label, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Ketoconazole and Rifampin on the Pharmacokinetics of AC220 and its Active Metabolite, AC886, in Healthy Volunteers

Conditions: Healthy Participants 		AC220-012 Lay Summaries
A Phase 1, Open-Label, randomized, Balanced, Single-Dose, Parallel Design AC220 Food Effect Study in Healthy Volunteers

Conditions: Healthy Participants 		AC220-008 Lay Summaries
A Phase 1 Study of the Absorption, Metabolism, and Elimination of AC220 in Healthy Normal Male Volunteers

Conditions: Healthy Participants 		AC220-006 Lay Summaries
A Phase 3, Open-label Study of JVC-001 in Healthy Japanese Children 5 to 6 Years of Age

Conditions: Prevention of Measles, Mumps and Rubella 		VN0102-A-J303
jRCT2080225022		 Results
A Phase 3, Randomized, Observer-blinded Study of Low and High titer JVC-001 in Healthy Japanese Children 1 Year of Age

Conditions: Prevention of Measles, Mumps and Rubella 		VN0102-A-J302
jRCT2080225025		 Results
A Phase 3, Randomized, Observer-blinded Study of JVC-001 Compared to Active-controlled in Healthy Japanese Children 1 Year of Age

Conditions: Prevention of Measles, Mumps and Rubella 		VN0102-A-J301
jRCT2080225026		 Results
A Phase 2, Randomized, Double-Blind, Dose Finding Study to Describe the Immunogenicity, Safety and Tolerability of VN-0200 in Japanese Adults Aged 60-80 Years

Conditions: Prevention of Respiratory Syncytial Virus Infection 		VN0200-091
NCT05547087		 Results
A Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of VN-0200 After Intramuscular Injections in Japanese Healthy Adults and Elderly Subjects

Conditions: Prevention of Respiratory Syncytial Virus Infection 		VN0200-A-J101
NCT04914520		 Results
A Phase 3, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children age 2 Years Through 18 Years

Conditions: Prevention of Influenza 		VN0107-A-J301
jRCT2080223345		 Results
A Phase III, Randomized, Active-comparator, Observer-blind, Non-inferiority Study to Demonstrate the Immunogenicity and Safety of DS-5670d (Monovalent: Omicron XBB.1.5) in Adults and Children Aged 12 Years and Older

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-237
jRCT2031230424		 Results
A Phase 2/3, Randomized, Active-controlled, Observer-blinded, Non-inferiority Study to Evaluate the Safety and Immunogenicity of Booster Immunization with DS-5670a/b (Bivalent: Original Strain/Omicron Strain BA.4-5) in Subjects Aged 5 to 11 Years Who Have Completed Initial Immunization with Comirnaty Intramuscular Injection (Univalent: Original Strain)

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-214
jRCT2031220665		 Results
A Phase 3, Randomized, Active-controlled, Observer-blinded, Non-inferiority Study to Evaluate the Safety and Immunogenicity of Booster Immunization with DS-5670a/b (Bivalent: Original Strain/Omicron Strain BA.4-5) in Subjects Aged 12 Years and Older Who Have Completed Initial and Booster Immunization with SARS-CoV-2 Vaccines

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-212
jRCT2071220111		 Results
A Phase II/III, Randomized, Active-comparator, Observer-blind, Non-inferiority Study to Demonstrate the Immunogenicity and Safety of DS-5670a/b (Bivalent: Original/Omicron BA.4-5) in Children 5 Through 11 Years of Age

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-203
jRCT2031220399		 Results
A Phase III, Randomized, Active-comparator, Non-inferiority Study to Demonstrate the Immunogenicity and Safety of DS-5670a (COVID-19 Vaccine) in Children 12 Through 17 Years of Age

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-202
jRCT2031220400		 Results
A Randomized, Active-comparator, Observer-blind, Phase I/II/III Study to Demonstrate the Immunogenicity of a Single Booster Dose of DS-5670a in Adults and Elderly Received a Primary Series of Approved COVID-19 Vaccine

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-146
jRCT2071210106		 Results
A Phase 3, Randomized, Active-Comparator, Observer-Blind, Non-Inferiority Study of DS-5670a (COVID-19 Vaccine) in Adults Aged 18 Years and Older

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-103
jRCT2031220264		 Results
A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

Conditions: Tenosynovial Giant Cell Tumor 		PL3397-A-U4003
NCT04526704		 Results
Lay Summaries
A Phase 2, Multicenter, Two-Part, Open-Label Study of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor in Japan

Conditions: Tenosynovial Giant Cell Tumor 		PL3397-A-J304
NCT04703322		 Results
A Long-term Study to Further Evaluate the Risk of Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Conditions: Tenosynovial Giant Cell Tumor 		PL3397-A-U401
NCT04635111
Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor

Conditions: Tenosynovial Giant Cell Tumor 		PL3397-A-A303
NCT04488822		 Results
An Open-label, Single-dose Study to Assess the Pharmacokinetics of Pexidartinib in Subjects With Moderate Hepatic Impairment Compared to Healthy Subjects

Conditions: Moderate Hepatic Impairment 		PL3397-A-U129
NCT04223635		 Results
An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients

Conditions: Tenosynovial Giant Cell Tumor/KIT-mutant Tumor/Other Solid Cancer 		PL3397-A-U126
NCT03291288		 Results
Lay Summaries
A Phase 1 Study of Single Agent Pexidartinib in Asian Subjects With Advanced Solid Tumors

Conditions: Advanced Solid Cancer 		PL3397-A-A103
NCT02734433		 Results
Lay Summaries
Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors

Conditions: Melanoma/Non-small Cell Lung Cancer/Head and Neck Cancer/Gastrointestinal Stromal Tumor (GIST)/Ovarian Cancer 		PLX108-14
NCT02452424		 Results
Lay Summaries
A Phase I/II Open Label, Multicenter Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Conditions: Melanoma 		PLX108-13
NCT02975700		 Results
Lay Summaries
A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath

Conditions: Pigmented Villonodular Synovitis/Giant Cell Tumor of the Tendon Sheath 		PLX108-10
NCT02371369		 Results
Lay Summaries
A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma

Conditions: Melanoma 		PLX108-09
NCT01826448		 Results
Lay Summaries
An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma 		PLX108-08
NCT01790503		 Results
Lay Summaries
A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

Conditions: Solid Cancer 		PLX108-07
NCT01525602		 Results
Lay Summaries
A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC) Counts

Conditions: Prostate Cancer 		PLX108-06
NCT01499043		 Results
Lay Summaries
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory FLT3-ITD Positive Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia 		PLX108-05
NCT01349049		 Results
Lay Summaries
A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma

Conditions: Glioblastoma 		PLX108-04
NCT01349036		 Results
Lay Summaries
A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Conditions: Hodgkin Lymphoma 		PLX108-03
NCT01217229		 Results
Lay Summaries
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology

Conditions: Solid Cancer 		PLX108-01
NCT01004861		 Results
Lay Summaries
A Phase 1, Open-Label, Randomized, 3-Period Crossover Study to Assess the Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Subjects

Conditions: Healthy Participants 		PL3397-A-U128
NCT03901313		 Results
An Open-label, Randomized, 2-treatment, 2-period, Crossover Study to Evaluate the Effect of Probenecid on the Pharmacokinetics of Pexidartinib in Healthy Subjects

Conditions: Healthy Participants 		PL3397-A-U122
NCT03138759		 Lay Summaries
A Phase 1, Single-dose and Multiple-dose Study of DS-2319b Inhalation Powder to Assess the Safety and Pharmacokinetics of DS-2319a in Healthy Japanese Subjects

Conditions: Healthy Participants 		DS2319-A-J101
jRCT2051200153		 Results
A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Conditions: Metastatic Castration-resistant Prostate Cancer		 DS3201-343
NCT07244341
A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations

Conditions: Non-small Cell Lung Cancer 		DS3201-330
NCT06644768
A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Conditions: Solid Tumors/Gastric Cancer/ Gastroesophageal Junction Cancer/Non-small Cell Lung Cancer 		DS3201-324
NCT06244485
Single-arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects With Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Conditions: Peripheral T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma 		DS3201-A-U202
NCT04703192		 Results
A Phase 2, Multicenter, Open-label, Single-arm Study of Valemetostat Tosylate (DS-3201b) in Patients With Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Conditions: Adult T-cell Leukemia/Lymphoma 		DS3201-A-J201
NCT04102150		 Results
Phase 1 Study of DS-3201b to Evaluate the Effect of Food (Low-fat Meal) on the Pharmacokinetics in Healthy Subjects

Conditions: Healthy Participants 		DS3201-A-J109
jRCT2071200043		 Results
Phase 1 Study of DS-3201b to Assess the Effects of Multiple Oral Administration of Rifampicin on the Pharmacokinetics of Single Oral Administration of DS-3201b Tablets in Healthy Japanese Subjects

Conditions: Healthy Participants 		DS3201-A-J107
jRCT2080225242		 Results
An Open-label, Single-dose Study to Assess the Pharmacokinetics of DS-3201b In Subjects With Hepatic Impairment

Conditions: Hepatic Impairment 		DS3201-A-U106
NCT04276662
Phase 1 Study of DS-3201b to Assess the Effects of Itraconazole and Fluconazole on the Pharmacokinetics of Single Oral Administration of DS-3201b Tablets in Healthy Japanese Subjects

Conditions: Healthy Participants 		DS3201-A-J104
jRCT2080223846		 Results
Phase 1 Study of DS-3201b to Evaluate the Pharmacokinetics and Safety After Single Oral Administration, the Relative Bioavailability After Administration of Tablet and Capsule Formulations, and the Effect of Food on the Pharmacokinetics in Healthy Japanese Subjects

Conditions: Healthy Participants 		DS3201-A-J103
jRCT2080223748		 Results
A Phase 1 Study of DS-3201b in Subjects With Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Conditions: Acute Myelogenous Leukemia/Acute Lymphocytic Leukemia 		DS3201-A-U102
NCT03110354		 Results
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas

Conditions: Non-hodgkin Lymphoma 		DS3201-A-J101
NCT02732275
A Phase 2 Study to Assess the Aafety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-116
jRCT2071210086		 Results
A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

Conditions: Prevention of infectious disease by SARS-CoV-2 		DS5670-A-J101
NCT04821674		 Results
Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Conditions: Duchenne Muscular Dystrophy 		DS5141-A-J101
NCT02667483		 Results
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Conditions: Atopic Dermatitis 		ASBI 704
NCT01756898		 Results
Effects of Bempedoic Acid/Ezetimibe/High-intensity Statin on Plaque Regression and Stabilisation of Coronary Atherosclerosis Among Patients Without Cardiovascular Events

Conditions: Coronary Atherosclerosis/Mixed Dyslipidemia/Hypercholesterolemia 		DSE-BMP-0005-CIS-MA
NCT07474649
A Randomized, Single-center, Open-label, Single-dose, 4-period, 2-sequence, Fully Replicate Crossover Study to Assess the Bioequivalence of a Test Fixed Dose Combination Product Versus the Co-administered Individual Reference Products Containing Bempedoic Acid 180 mg / Ezetimibe 10 mg and Rosuvastatin 20 mg in Healthy Participants

Conditions: Healthy Participants 		DSE-BMP-0004-CIS-MA
NCT07201545
A Randomized, Single-center, Open-label, Single-dose, 4-period, 2-sequence, Fully Replicate Crossover Study To Assess The Bioequivalence of a Test Fixed Dose Combination Product Versus The Co-administered Individual Reference Products Containing Bempedoic Acid 180 mg / Ezetimibe 10 mg And Atorvastatin 40 mg In Healthy Participants

Conditions: Healthy Participants 		DSE-BMP-0003-CIS-MA
NCT07268625
A Randomized, Single-center, Open-Label, Single-dose, 4-Period, 2-Sequence, Fully Replicate Crossover Study To Assess The Bioequivalence Of A Test Fixed Dose Combination Product Versus The Co-Administered Individual Reference Products Containing Bempedoic Acid 180 mg, Ezetimibe 10 mg And Rosuvastatin 20 mg In Healthy Participants

Conditions: Healthy Participants 		DSE-BMP-0002-CIS-MA
NCT07182383
A Randomized, Single-Center, Open-Label, Single-Dose, 4-Period, 2-Sequence, Fully Replicate Crossover Study To Assess The Bioequivalence Of A Test Fixed Dose Combination Product Versus The Co-Administered Individual Reference Products Containing Bempedoic Acid 180 MG, Ezetimibe 10 mg And Atorvastatin 40 mg In Healthy Participants

Conditions: Healthy Participants 		DSE-BMP-0001-CIS-MA
NCT07235189
A Multicenter, Prospective, Phase IV, Interventional Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan (CLEAR Taiwan)

Conditions: Primary Hypercholesterolemia/Mixed Hyperlipidemia 		BA-TWMA-HLD-4001
NCT06925100
Colesevelam Oral Suspension as Monotherapy or Add-on to Metformin Therapy in Pediatric Subjects With Type 2 Diabetes Mellitus (WELKid DM)

Conditions: Pediatric Type 2 Diabetes Mellitus 		WEL-A-U307
NCT01258075		 Results
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)

Conditions: Type 2 Diabetes Mellitus 		WEL-A-U306
NCT00789750		 Results
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol as Monotherapy for Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		WEL-305
NCT00789737		 Results
Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug naïve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes

Conditions: Type 2 Diabetes Mellitus/Hyper-cholesterolemia/Pre-diabetes 		WEL-411
NCT00570739		 Results
Effects of Colesevelam HCl, Avandia® (Rosiglitazone Maleate), or JanuviaTM (Sitagliptin) on Glycemic Parameters and Lipid Profiles in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy

Conditions: Type 2 Diabetes Mellitus 		WEL-409
NCT00484419		 Results
Effects of Colesevelam on Insulin Sensitivity in Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		WEL-201
NCT00147745		 Results
Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients With Heterozygous Familial Hypercholesterolemia on a Stable Dose of Statins or Treatment Naive to Lipid-lowering Therapy

Conditions: Hyper-cholesterolemia 		WEL-410
NCT00145574		 Results
A Multicenter, Prospective, Non-interventional Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation (SILVERCARE_AF)

Conditions: Atrial Fibrillation 		LIX-OS-22-01
NCT05804747
A Descriptive Non-interventional Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice for Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

Conditions: Atrial Fibrillation 		EDX/18/0414(2)
NCT05262322
Real-world Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation in China (ETNA-AF-CHINA)

Conditions: Non-valvular Atrial Fibrillation 		DSCN-ETNA AF-RWS-001
NCT04747496
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR)

Conditions: Atrial Fibrillation 		ETAF-TR-01
NCT04594915
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - German Non-interventional Study (ENCOURAGE-AF)

Conditions: Non-valvular Atrial Fibrillation 		DS-EDO-01-20-DE
NCT04519944
An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events

Conditions: Cardiac Disease 		DU176b-C-U313
NCT03395639		 Results
Lay Summaries
Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation (ENVISAGE-TAVI AF)

Conditions: Atrial Fibrillation 		DU176b-C-U4001
NCT02943785		 Results
Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)

Conditions: Atrial Fibrillation/Venous Thromboembolism 		DSE-EDO-02-15-EU
NCT02950168
Evaluation of Edoxaban in Anticoagulant Naïve Patients With Nonvalvular Atrial Fibrillation (NVAF) and High Creatinine Clearance

Conditions: Atrial Fibrillation 		DU176b-C-E314
NCT02964949		 Results
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe (ETNA-VTE)

Conditions: Venous Thromboembolism 		DSE-EDO-05-14-EU
NCT02943993		 Results
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (ETNA-AF-EU)

Conditions: Atrial Fibrillation 		DSE-EDO-04-14-EU
NCT02944019
A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)

Conditions: Atrial Fibrillation 		DSE-EDO-01-16-EU
NCT02942576		 Results
Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement (ENTRUST-AF-PCI)

Conditions: Atrial Fibrillation 		DSE-EDO-01-15-EU
NCT02866175		 Results
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of DU-176b in Patients With NVAF Aged 80 Years or Older Who Are Ineligible for Available Oral Anticoagulation Therapy

Conditions: Atrial Fibrillation 		DU176b-C-J316
NCT02801669		 Results
A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)

Conditions: Venous Thromboembolism (VTE)/Pulmonary Embolism/Deep Vein Thrombosis (DVT) 		DU176b-D-U312
NCT02798471		 Results
Lay Summaries
A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

Conditions: Deep Vein Thrombosis/Venous Thromboembolism 		DU176b-A-U157
NCT02303431		 Results
A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer

Conditions: Venous Thromboembolism/Deep Vein Thrombosis/Pulmonary Embolism/Cancer 		DU176b-D-U311
NCT02073682		 Results
A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial Fibrillation (ENSURE-AF)

Conditions: Atrial Fibrillation 		DU176b-F-E308
NCT02072434		 Results
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention

Conditions: Peripheral Arterial Disease 		DU176b-E-U210
NCT01802775		 Results
Phase III Clinical Study of DU-176b (Non-valvular Atrial Fibrillation): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Non-valvular Atrial Fibrillation and Severe Renal Impairment (SRI)

Conditions: Non-valvular Atrial Fibrillation 		DU176b-B-J307
NCT01857622		 Results
Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs

Conditions: Venous Thromboembolism 		DU176b-B-J306
NCT01857583		 Results
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis - Edoxaban Thrombus Reduction Imaging Study

Conditions: Deep Vein Thrombosis/Venous Thrombosis 		DU176b-D-U211
NCT01662908		 Results
A Phase 2b, Randomized, Multi-Dose Efficacy,Safety Study of the Oral Factor Xa Inhibitor DU-176b Versus Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-2)

Conditions: Venous Thromboembolism/Thromboembolism/Thrombosis/Deep Vein Thrombosis/Arthroplasty/Hip Replacement 		DU176b-B-J209
NCT01203098		 Results
A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE) (Hokusai-VTE)

Conditions: Deep-Vein Blood Clots/Lung Blood Clots 		DU176b-D-U305
NCT00986154		 Results
A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)

Conditions: Venous Thromboembolism 		DU176b-B-J304
NCT01181167		 Results
A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)

Conditions: Venous Thromboembolism 		DU176b-B-J303
NCT01181141		 Results
A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial)

Conditions: Venous Thromboembolism 		DU176b-B-J302
NCT01181102		 Results
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (Engage-AF TIMI-48)

Conditions: Atrial Fibrillation 		DU176b-C-U301
NCT00781391		 Results
A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects With Non-Valvular Atrial Fibrillation

Conditions: Atrial Fibrillation 		DU176b-C-J226
NCT00806624		 Results
A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation

Conditions: Atrial Fibrillation 		DU176b-C-J225
NCT00829933		 Results
A Phase 2b, Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Dose-finding Study of the Oral Factor Xa Inhibitor DU-176b Compared With Placebo for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS J-1)

Conditions: Venous Thromboembolism 		DU176b-04
NCT01203072		 Results
A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation

Conditions: Atrial Fibrillation 		DU176b-PRT018
NCT00504556		 Results
A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement

Conditions: Thrombosis/Hip Replacement 		DU176b-PRT011
NCT00398216		 Results
A Phase IIa, Multi-center, Multi-national, Open Label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty

Conditions: Arthroplasty/Hip Replacement/Thrombosis 		DU176b-PRT007
NCT00107900		 Results
The Effect of the Co-administration of Multiple Oral Doses of the Fructose-1,6-Bisphosphatase (FBPase) Inhibitor CS-917 and Glibenclamide on Pharmacokinetics, Safety and Tolerability in Diabetic Patients (NIDDM)

Conditions: Type 2 Diabetes Mellitus 		CS0917-A-E-107
2004-003195-11		 Results
A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (DESIRABLE)

Conditions: Rheumatoid Arthritis 		AMG162-D-J301
NCT01973569		 Results
A Dose-response Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on Methotrexate (MTX) to Validate Inhibitory Effect on Bone Erosion (DRIVE)

Conditions: Rheumatoid Arthritis 		AMG162-D-J201
jRCT2080221226		 Results
A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s) (DIRECT)

Conditions: Osteoporosis 		AMG162-A-J301
NCT00680953		 Results
A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma

Conditions: Glioma 		DS1001-A-J201
NCT04458272
A Phase 1 Study of DS-1001b in Patients With IDH1 Mutated Gliomas

Conditions: Glioma 		DS1001-A-J101
NCT03030066
A Phase I Open-Label Study to Evaluate the Mass Balance and Pharmacokinetics of [14C]DS-1001b Following Single Oral Administration to Healthy Adult Male Subjects

Conditions: Healthy Participants 		DS1001-171
jRCT2071240033		 Results
A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Gefitinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer 		DS1205-A-J102
NCT03599518		 Results
A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer		 DS1205-A-U101
NCT03255083		 Results
A Phase I, Single Blind, Placebo-controlled, Randomized Study to Assess the Safety of DS-1040b in Subjects With Thrombectomy Treated Acute Ischemic Stroke

Conditions: Acute Ischemic Stroke 		DS1040-A-J110
NCT03198715		 Results
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b When Added to Standard of Care Anticoagulation Therapy in Subjects With Acute Submassive Pulmonary Embolism

Conditions: Acute Submassive Pulmonary Embolism 		DS1040-B-U107
NCT02923115		 Results
A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke (ASSENT)

Conditions: Acute Ischemic Stroke 		DS1040-A-U103
NCT02586233		 Results
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease

Conditions: Chronic Obstructive Pulmonary Disease 		ASBI 307
NCT00698828		 Results
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors

Conditions: Solid Cancer 		DS2248-A-U101
NCT01288430		 Results
Single-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-6016a After Subcutaneous Injection in Healthy Japanese Subjects

Conditions: Healthy Participants 		DS6016-A-J101
NCT04818398		 Results
Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects With Advanced Gastrointestinal Stromal Tumor

Conditions: Gastrointestinal Stromal Tumor 		DS6157-A-U101
NCT04276415		 Results
A Study of CS-3150 to Evaluate Safety in Japanese Type 2 Diabetic Patients with Macroalbuminuria

Conditions: Type 2 Diabetes 		CS3150-B-J309
jRCT2080223640		 Results
A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Placebo in Japanese Type 2 Diabetic Patients with Microalbuminuria (ESAX-DN)

Conditions: Type 2 Diabetes 		CS3150-B-J308
jRCT2080223639		 Results
A Study of CS-3150 to Evaluate Efficacy and Safety in Patients With Primary Aldosteronism

Conditions: Primary Aldosteronism 		CS3150-A-J307
NCT02885662		 Results
A Study of CS-3150 to Evaluate Efficacy and Safety in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Conditions: Hypertension With Type 2 Diabetes and Albuminuria 		CS3150-A-J306
NCT02807974		 Results
A Study of CS-3150 to Evaluate Efficacy and Safety in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Conditions: Moderate Renal Impairment/Hypertension 		CS3150-A-J305
NCT02807987		 Results
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Patients With Severe Hypertension (Grade III)

Conditions: Severe Hypertension 		CS3150-A-J304
NCT02808026		 Results
An Exploratory Study of CS-3150 to Evaluate the Relation Between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients With Essential Hypertension

Conditions: Essential Hypertension 		CS3150-A-J303
NCT02848170		 Results
Open-label, Multicenter, Interventional, Dose Titration Study to Assess the Long-term Study of CS-3150 2.5mg and 5mg Alone as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Conditions: Essential Hypertension 		CS3150-A-J302
NCT02722265		 Results
A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN)

Conditions: Essential Hypertension 		CS3150-A-J301
NCT02890173		 Results
A Multi-center, Open Label, Dose Titration, Exploratory Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment

Conditions: Hypertension/Moderate Renal Impairment 		CS3150-A-J206
NCT02448628		 Results
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Hypertension

Conditions: Hypertension 		CS3150-A-J203
NCT02345044		 Results
Phase 2 Study to Evaluate Efficacy and Safety of CS-3150 in Patients with Essential Hypertension

Conditions: Hypertension 		CS3150-A-J201
jRCT2080221876		 Results
A Bioequivalence Study of CS-3150 - Evaluation of Bioequivalence Between Esaxerenone 5mg Tablet and Esaxerenone 5mg OD Tablet (CS-3150 OD Tablet) in Healthy Japanese Subjects -

Conditions: Healthy Participants 		CS3150-C-J101
jRCT1080224760		 Results
Clinical Pharmacology Study of CS-3150 A Single Dose Study to Assess the Absolute Bioavailability and Effect of Food on the Pharmacokinetics of CS-3150 in Japanese Healthy Subjects

Conditions: Healthy Participants 		CS3150-A-J112
jRCT2080223397		 Results
Clinical Pharmacology Study of CS-3150 Drug-drug Interaction Study Between CS-3150 and Digoxin or Rifampicin in Healthy Japanese Subjects

Conditions: Healthy Participants 		CS3150-A-J111
jRCT2080223388		 Results
Clinical Pharmacology Study of CS-3150 Drug-drug Interaction Study Between CS-3150 and Amlodipine in Healthy Japanese Subjects

Conditions: Healthy Participants 		CS3150-A-J110
jRCT2080223324		 Results
Clinical Pharmacology Study of CS-3150 A Single-dose Study to Assess the Pharmacokinetics and Safety of CS-3150 in Japanese Subjects With Varying Degrees of Hepatic Function

Conditions: Hepatic Impairment 		CS3150-A-J109
jRCT2080223284		 Results
Clinical Pharmacology Study of CS-3150 Evaluation of the Effect of Repeated Dose of Itraconazole Orally Administered to Healthy Japanese Adult Male on the Pharmacokinetics of CS-3150

Conditions: Healthy Participants 		CS3150-A-J108
jRCT2080223231		 Results
An Open-label, Single-sequence Crossover Study to Evaluate the Effects of CS-3150 on the Pharmacokinetics of Midazolam in Japanese Healthy Subjects

Conditions: Healthy Participants 		CS3150-A-J107
jRCT2080222780		 Results
A Phase 1 Study of CS-3150 Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics after Multiple Oral Administration in Japanese Healthy Adult Male Subjects

Conditions: Healthy Participants 		CS3150-A-J102
jRCT2080223421		 Results
A Phase 1 Study of CS-3150 Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics After Single Oral Administration in Japanese Healthy Adult Male Subjects

Conditions: Healthy Participants 		CS3150-A-J101
jRCT2080223418		 Results
Phase 1b Study of CS-7017 in Combination With Erlotinib in Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Who Failed First-line Therapy

Conditions: Non-Smal Cell Lung Cancer 		CS7017-A-A110
NCT01199068		 Results
Phase 1b Study of CS-7017 in Combination With Carboplatin/Paclitaxel in Chemotherapy-naïve Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Conditions: Non-Smal Cell Lung Cancer 		CS7017-A-A108
NCT01199055		 Results
Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy

Conditions: Lung Cancer 		CS7017-A-U204
NCT01101334		 Results
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

Conditions: Colorectal Cancer 		CS7017-A-U203
NCT00967616		 Results
Phase 2 Randomized Study of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-Naïve Subjects With Metastatic Non-Small Cell Lung Cancer

Conditions: Lung Cancer 		CS7017-A-U202
NCT00806286		 Results
A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy

Conditions: Colorectal Cancer 		CS7017-A-E201
NCT00986440		 Results
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer 		CS7017-A-U103
NCT00603941		 Results
Extended Use of CS 7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Subjects With Cancer

Conditions: Cancer 		CS7017-A-U102E
NCT00881569		 Results
A Phase I Dose Finding Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Patients With Advanced or Malignancies

Conditions: Neoplasm 		CS7017-A-U102
NCT00408434		 Results
Open Study of Quadrivalent VN-100 in Healthy Children

Conditions: Prevention of Influenza 		VN100-A-J303
jRCT2080222939		 Results
Open Study of Quadrivalent VN-100 in Japanese Healthy Volunteers

Conditions: Prevention of Influenza 		VN100-A-J302
jRCT2080222562		 Results
A Randomized, Double-blind, Confirmatory Study of VN-100 in Healthy Elderly Volunteers

Conditions: Prevention of Influenza 		VN100-A-J301
jRCT2080222443		 Results
A Randomized, Double-blind, Comparative Study of VN-100 in Healthy Adult Japanese Volunteers

Conditions: Prevention of Influenza 		VN100-A-J101
jRCT2080222050		 Results
CS-8958 Phase 3 Study in Pediatric Patients < 10 Years of Age - A Open-labeled Atudy of Nebulized CS-8958 in the Treatment of Influenza Virus Infection -

Conditions: Influenza 		CS8958-B-J311
jRCT2080223343		 Results
CS-8958 Phase 3 Study - A Randomized, Single-blind, Placebo-controlled Study of Nebulized CS-8958 in the Treatment of Influenza Virus Infection -

Conditions: Influenza 		CS8958-B-J310
jRCT2080223342		 Results
A Phase 3 Study of CS-8958 (Prophylaxis of Single Administration) - A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Single Dose Administration for the Prevention of Influenza Virus Infection -

Conditions: Influenza (Prophylaxis) 		CS8958-A-J309
jRCT2080222628		 Results
A Phase 3 Study of CS-8958 (Prophylaxis for Children) - A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy for the Prevention of Influenza Virus Infection in Children Under 10 Years-

Conditions: Influenza (Prophylaxis) 		CS8958-A-J308
jRCT2080222627		 Results
A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection (MARVEL)

Conditions: Influenza 		CS8958-A-J301
NCT00803595		 Results
CS-8958 Clinical Pharmacology Study - Safety and Pharmacokinetics of Nebulized Laninamivir Octanoate (CS-8958) After A Single Inhaled Administration in Healthy Male Japanese Subjects -

Conditions: Healthy Participants 		CS8958-B-J109
jRCT2080222944		 Results
An Open-label, Randomized, Clinical Study Assessing the Safety and Immunogenicity of JVC-001 in Japanese Healthy Children

Conditions: Prevention of Measles, Mumps and Rubella 		JVC-001-P12-01
jRCT2080222978		 Results
An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension

Conditions: Central Neuropathic Pain 		DS5565-A-J314
NCT03901352		 Results
A Japanese, Phase 3, Open-label, 14-Week Study of DS-5565 in Patients With Pain Associated With Diabetic Peripheral Neuropathy With Renal Impairment of Post-herpetic Neuralgia With Renal Impairment

Conditions: Renal Impairment/Diabetic Peripheral Neuropathic Pain/Post-herpetic Neuralgia 		DS5565-A-J313
NCT02607280		 Results
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Conditions: Pain Associated with Fibromyalgia 		DS5565-A-E312
NCT02234583		 Results
A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

Conditions: Fibromyalgia 		DS5565-A-E311
NCT02187159		 Results
A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

Conditions: Pain Associated With Fibromyalgia 		DS5565-A-E310
NCT02187471		 Results
A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

Conditions: Fibromyalgia 		DS5565-A-E309
NCT02146430		 Results
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease

Conditions: Fibromyalgia		 DS5565-A-U307
NCT02496884		 Results
An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension

Conditions: Post-herpetic Neuralgia 		DS5565-A-J304
NCT02318719		 Results
An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Diabetic Peripheral Neuropathic Pain Followed by a 52-Week Open-label Extension

Conditions: Diabetic Peripheral Neuropathic Pain 		DS5565-A-J303
NCT02318706		 Results
An Asian, Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Pregabalin-controlled, Dose-finding Study of DS-5565 in Patients With Pain Associated With Diabetic Peripheral Neuropathy

Conditions: Type 2 Diabetes Mellitus/Diabetic Peripheral Neuropathic Pain 		DS5565-A-J202
NCT01504412		 Results
A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 for Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Conditions: Diabetic Peripheral Neuropathy 		DS5565-A-U201
NCT01496365		 Results
A Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of DS-5565 in Healthy Chinese Subjects

Conditions: Healthy Participants 		DS5565-A-A118
jRCT1080223624		 Results
DS-5565 Clinical Pharmacology Study An Open-Label, Single-Dose Study to Assess the Pharmacokinetics and Safety of DS-5565 in Japanese Subjects with Varying Degrees of Renal Function

Conditions: Renal Dysfunction 		DS5565-A-J115
jRCT2080222129		 Results
A Phase 1 Study of Milademetan in Combination With Quizartinib in Subjects With FLT3-ITD Mutant Acute Myeloid Leukemia That Are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy

Conditions: Acute Myeloid Leukemia 		DS3032-A-U105
NCT03552029		 Results
Phase 1, Open-label, Dose Escalation Study of Milademetan, an Oral MDM2 Inhibitor, to Assess Safety, Tolerability and Pharmacokinetics in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia 		DS3032-A-J104
NCT03671564		 Results
A phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Japanese Subjects with Advanced Solid Tumors or Lymphomas

Conditions: Solid Cancer/Lymphomas 		DS3032-A-J103
jRCT2080222642		 Results
A Phase 1 Study of Milademetan (DS 3032b), an Oral MDM2 Inhibitor, In Dose Escalation as a Single Agent and In Dose Escalation/Expansion In Combination With 5 Azacitidine In Subjects With Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Conditions: Hematological Malignancies 		DS3032-A-U102
NCT02319369		 Results
A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

Conditions: Advanced Solid Cancer/Lymphomas 		DS3032-A-U101
NCT01877382		 Results
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

Conditions: Type 2 Diabetes Mellitus 		DS8500-A-U202
NCT02647320		 Results
Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension

Conditions: Hypertension 		CS0866-A-U301
NCT00151775		 Results
Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome

Conditions: Metabolic Syndrome/Hypertension 		DSE-866/47
NCT00676845		 Results
Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome

Conditions: Metabolic Syndrome/Hypertension 		DSE-866/46
NCT00891267		 Results
CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus (ORIENT)

Conditions: Diabetic Nephropathy/Type 2 Diabetes Mellitus/Proteinuria 		149-011/150-008
NCT00141453		 Results
A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects

Conditions: Hypertension 		CS0866-A-U452
NCT00949884		 Results
Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension (OLMETREAT)

Conditions: Mild to Moderate Hypertension 		SP-OLM-03-05
NCT00311155		 Results
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (OLMEBNP)

Conditions: Chronic Heart Failure/High Blood B-type (or Brain) Natriuretic Peptide Level 		DSE-866-45
NCT00679484		 Results
An Open-label Study of the Single-dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension

Conditions: Hypertension 		CS0866-A-U102
NCT00151814		 Results
A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension

Conditions: Hypertension 		866-451
NCT00430638		 Results
Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)

Conditions: Type 2 Diabetes Mellitus/Cardiovascular Disease/Kidney Disease 		SE-866/44
NCT00185159		 Results
Add-on Study of CCBs or Diuretics in Essential Hypertension Not Achieving Target Blood Pressure on Olmesartan Medoxomil Alone

Conditions: Hypertension 		OLM004-071
NCT00858702		 Results
A Prospective, Open Label, Single Arm Study to Evaluation the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Elderly Patients With Hypertension

Conditions: Hypertension 		866-450
NCT00412932		 Results
A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker "Olmesartan Medoxomil" Versus "Losartan" in Patients With Mild to Moderate Essential Hypertension

Conditions: Hypertension 		TSP-866/01
NCT00857285		 Results
National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine Besylate

Conditions: Essential Hypertension 		SPB-OM-0106
NCT00890591		 Results
A Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of a Compounded 4 mg/mL Olmesartan Medoxomil Suspension (Total Dose 40 mg) and 40 mg Olmesartan Medoxomil Tablets (Benicar®) in Healthy Adult Volunteers Under Fasting Conditions

Conditions: Healthy Participants 		CS0866-A-U101
2015-003005-41		 Results
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy (BP CRUSH)

Conditions: Hypertension 		CS8663-404
NCT00791258		 Results
A Prospective, Open-label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil and Amlodipine Based Treatment Regimen in Hypertensive, Type 2 Diabetic Subjects

Conditions: Type 2 Diabetes Mellitus/Hypertension 		CS-8663-403
NCT00654745		 Results
A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension

Conditions: Hypertension 		8663-402
NCT00527514		 Results
Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone

Conditions: Essential Hypertension 		CS8663-A-E303
NCT00220233		 Results
Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy

Conditions: Essential Hypertension 		CS8663-A-E302
NCT00220220		 Results
Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone

Conditions: Essential Hypertension 		CS8635-A-E303
NCT00902538		 Results
Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension

Conditions: Essential Hypertension 		CS8635-A-E302
NCT00923091		 Results
A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension

Conditions: Hypertension 		CS8635-A-U301
NCT00649389		 Results
A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension

Conditions: Type 2 Diabetes Mellitus 		866-449
NCT00403481		 Results
Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy

Conditions: Essential Hypertension 		CS866CM-B-E302
NCT00430950		 Results
Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy

Conditions: Hypertension 		CS866CM-B-E301
NCT00430508		 Results
A Bioequivalence Study of DS-5058b (Immediate-release Tablet) and Oxycodone Hydrochloride Hydrate in Healthy Japanese Subjects

Conditions: Healthy Participants 		DS5058-C-J106
jRCT1080223737		 Results
Clinical Pharmacology Study of DS-5058b Immediate-release and Extended-release Tablets in Healthy Japanese Subjects

Conditions: Healthy Participants 		DS5058-C-J104
jRCT1080223551		 Results
Bioequivalence of DS-5058b (Extended-release Tablet) to Oxycodone Hydrochloride Hydrate in Healthy Japanese Subjects

Conditions: Healthy Participants 		DS5058-A-J101
jRCT1080223420		 Results
CS-747S PhaseIII Trial -A Double-blind Study of CS-747S Versus Clopidogrel Sulfate in Patients With Thrombotic Stroke Having Risk Factors for Stroke Recurrence-

Conditions: Thrombotic Stroke 		CS0747S-A-J305
jRCT2080224080		 Results
CS-747S PhaseIII Trial -Double-blind Study of CS-747S Versus Clopidogrel Bisulfate in Elderly and/or Low Body Weight Patients With Ischemic Cerebrovascular Accident-

Conditions: Cerebrovascular Accident 		CS0747S-A-J304
jRCT2080221856		 Results
CS-747S Phase III Trial -Non-inferiority Study of CS-747S Versus Clopidogrel Bisulfate in Patients With Ischemic Cerebrovascular Accident-

Conditions: Cerebrovascular Accident 		CS0747S-A-J303
jRCT2080221542		 Results
CS-747S Clinical Pharmacology Study

Conditions: Stroke 		CS0747S-A-J203
jRCT2080221011		 Results
Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan

Conditions: Acute Coronary Syndrome		 CS747S-B-A4003
NCT03672097		 Results
A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents

Conditions: Coronary Artery Disease 		CS747S-B-U4003
NCT01587651		 Results
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease

Conditions: Coronary Artery Disease 		CS747S-B-U4002
NCT01260584		 Results
Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease

Conditions: Coronary Artery Disease 		CS747S-B-U4001
NCT01014624		 Results
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy

Conditions: Lung Cancer/Non-small Cell Lung Cancer 		U31287-A-U301
NCT02134015		 Results
Randomized, Placebo-controlled, Double-blind Phase 2 Study of Patritumab (U3-1287) in Combination With Cetuximab Plus Platinum-based Therapy in First Line Setting in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Conditions: Head and Neck Cancer 		U31287-A-U203
NCT02633800		 Results
Open-Label, Non-Randomized Study of U3-1287 in Combination With Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer		 U31287-A-U201E
2013-000104-42		 Results
Randomized, Placebo-controlled, Double-blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Erlotinib in EGFR Treatment Naïve Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Chemotherapy

Conditions: Lung Cancer 		U31287-A-U201
NCT01211483		 Results
A Double-Blind, Placebo-Controlled, Preliminary Study of the Efficacy, Safety, and Tolerability of Intravenous SUN N4057 in Patients With Motor Complications Associated With Parkinson's Disease

Conditions:: Parkinson's Disease 		ASBI-501
NCT00623363		 Results
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI

Conditions: Acute Ischemic Stroke 		SPI-103
NCT00272909		 Results
A Randomized, Double-blind, Placebo, and Active Comparator-controlled, Parallel-group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		CS0011-A-U302
NCT00571519		 Results
A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		CS0011-A-U301
NCT00484198		 Results
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury

Conditions: Acute Spinal Cord Injury 		ASBI 603
NCT01502631		 Results
Phase 2 Study of CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or Metastatic Ovarian Cancer

Conditions: Ovarian Cancer 		CS1008-A-U205
NCT00945191		 Results
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma

Conditions: Liver Cancer 		CS1008-A-U204
NCT01033240		 Results
A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen

Conditions: Colorectal Cancer 		CS1008-A-E203
NCT00969033		 Results
Randomised, Double-Blinded, Placebo Controlled, Phase 2 Study of CS-1008 in Combination With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer 		CS1008-A-E202
NCT00991796		 Results
Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer

Conditions: Pancreatic Cancer 		CS1008-A-U201
NCT00521404		 Results
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy

Conditions: Inoperable Hepatocellular Carcinoma		 ARQ197-A-U303
NCT01755767		 Results
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)

Conditions: Non-squamous/Non-small Cell Lung Cancer 		ARQ197-A-U302
NCT01244191		 Results
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy

Conditions: Colorectal Cancer 		ARQ197-A-U252
NCT01075048		 Results
Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors

Conditions: Non-CNS Germ Cell Tumors		 ARQ197-A-U251
NCT01055067		 Results
Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe - a MultInatioNal ObservatIonal Study (SANTORINI)

Conditions: Dyslipidemic/Atherosclerotic Cardiovascular Disease/Hyper-cholesterolemia		 DSE-HCL-01-19-EU
NCT04271280		 Results
A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS)

Conditions: Tenosynovial Giant Cell Tumors 		DS-ONC-01-15-EU
NCT02948088		 Results
A Multicenter Observational Study to Evaluate the Simplified STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Obtained Between 24 and 48 Hours of a Nonhemorrhagic Ischemic Stroke

Conditions: Nonhemorrhagic Ischemic Stroke 		ASBI 801
NCT01496885		 Results
A Phase II Study of DJ-927 Administered Orally Once Every Three Weeks as Second Line Therapy to Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Failure of a Platinum-based Non-taxane Regimen

Conditions: Non-small Cell Lung Cancer		 927E-PRT007
2004-000696-34		 Results
Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China: A Retrospective Real-world Study (REHEARSAL)

Conditions: HER2-positive Gastric Cancer/HER2-positive Gastroesophageal Junction Cancer 		DS8201-0014-NIS-MA
NCT06585501
Assessing Risk Factors Associated With the Onset of Oral Mucositis/Stomatitis and Ocular Surface Events (OSE) in Patients With Non-small Cell Lung Cancer (NSCLC) and HER2-negative Breast Cancer (BC)

Conditions: Advanced or Metastatic HER2-negative Breast Cancer/Advanced or Metastatic NSCLC 		DS1062-0008-NIS-EPI
NCT06686602
Prevalence of Brain Metastases and Impact on Survival in Metastatic Non-small Cell Lung Cancer by Line of Treatment

Conditions: Metastatic Non-small Cell Lung Cancer (mNSCLC) 		DS1062-0003-NIS-EPI
NCT06557967
Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatment: a Multi-center, Non-interventional and Retrospective Real-world Study (RECAP)

Conditions: Non-small Cell Lung Cancer (NSCLC) 		DS1062-0001-NIS-MA
NCT06617390
A Prospective, Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

Conditions: Diabetic Peripheral Neuropathic Pain 		DS5565-0002-NIS-MA
NCT06812117
Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China: A Retrospective, Database, Multi-center Study (ReTARdant)

Conditions: Diabetic Peripheral Neuropathic Pain (DPNP)/Chemotherapy-induced Peripheral Neuropathy (CIPN) 		DS5565-0001-NIS-MA
NCT06546202
Identify Predictors of Clinical Outcomes in Real-world Patients With HR+ and HER2-low/Negative Breast Cancer Treated With Neoadjuvant Chemotherapy or Endocrine Therapy

Conditions: Hormone-receptor-positive Breast Cancer/HER2-low Breast Cancer/HER2-negative Breast Cancer 		U31402-0005-NIS-EPI
NCT06040593
HER3 Prevalence in Archival Tissue and Associated Real World (RW) Data From Non-Small Cell Lung Cancer Patients

Conditions: Non-small Cell Lung Cancer 		U31402-0003-NIS-MA
NCT05769764
A Multicenter, Non-interventional Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

Conditions: HER2-positive Breast Cancer 		DSCN-EHT-NIS-BC001
NCT05769751
Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study

Conditions: Primary Hypercholesterolemiia/Mixed Dyslipidemia 		DSE-BMP-01-24-EU
NCT06686615
Non-Interventional Study On The Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia

Conditions: Primary Hypercholesterolemia/Mixed Dyslipidemia 		DSE-BMP-01-22-EU
NCT05798390
Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)

Conditions: Hyper-cholesterolemia/Mixed Dyslipidemia 		DSE-BMP-01-20-EU
NCT04579367
A Multinational, Multicenter, Non-Interventional, Retrospective, Observational, Real-World Study: Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in East Asia (HER2+ GASTA Study)

Conditions: Gastric Cancer 		DS-ASCAHQ-ENH-GC001
NCT05606094
SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® (Fixed Dose Combination of Bempedoic Acid 180mg and Ezetimibe 10mg) as add-on to Treatment With Maximally Tolerated Statin Therapy in Routine Clinical Practice

Conditions: Hypercholesterolemia/Mixed Dyslipidemia 		SYROS-DSE-BMP-01-21-EU
NCT05546398
DS-7113b Injection Phase II/III Study An Open Label and Extension Study of DS-7113 Injection in Patients With Cancer Pain (Subcutaneous Injection)

Conditions: Cancer Pain 		DS7113-C-J306
jRCT2080222685
DS-7113b Injection Phase II/III Study An Open Label and Extension Study of DS-7113 Injection in Patients With Cancer Pain (Intravenous Administration)

Conditions: Cancer Pain 		DS7113-C-J305
jRCT2080222684
DS-7113b Extended-release (ER) Tablet Phase III Study-A DS-7113b Extended-release Tablet Long-term Study in Patients With Cancer Pain-

Conditions: Cancer Pain 		DS7113-B-J304
jRCT2080222616
DS-7113b Extended-release (ER) Tablet Phase III Study-A Randomized Double-blind Comparison Study With Extended-release Oxycodone in Opioid-naive Patients With Cancer Pain-

Conditions: Cancer Pain 		DS7113-B-J303
jRCT2080222615
DS-7113b Phase III Study A DS-7113b Immediate Release (IR) Tablet Long-term Study in Patients With Cancer Pain

Conditions: Cancer Pain 		DS7113-A-J302
jRCT2080222239
DS-7113b Phase III Study A Randomized Double-blind Comparison Study With Immediate Release (IR) Oxycodone in Opioid-naive Patients With Cancer Pain

Conditions: Cancer Pain 		DS7113-A-J301
jRCT2080222289
DS-7113b Phase II Study -A DS-7113b Potency Ratio Assessment Atudy in Patients With Cancer Pain-

Conditions: Cancer Pain 		DS7113-A-J201
jRCT2080222120
Clinical Trial of KIB-PCI in Healthy Japanese Children

Conditions: Prevention of Influenza 		KIBPCI-A-J303
jRCT2080222503
A Randomized, Double-blind, Controlled Study of KIB-PCI in Japanese Healthy Adult Volunteers

Conditions: Prevention of Influenza 		KIBPCI-A-J302
jRCT2080221923
Confirmatory Clinical Trial of KIB-PCI in Healthy Adult Japanese Volunteers

Conditions: Prevention of Influenza 		KIBPCI-A-J301
jRCT2080221874
Exploratory Clinical Trial of KIB-PCI in Healthy Japanese Children

Conditions: Prevention of Influenza 		KIBPCI-A-J201
jRCT2080222144
Clinical Trial of VN-0104 in Japanese Healthy Adult Volunteers

Conditions: Prevention of Influenza 		VN0104-A-J201
jRCT2080222536
A Phase 3 Study of CS-8958 (Postexposure Prophylaxis 2011) - A Randamized, Double-blind, Placebo-controlled Study to Confirm the Efficacy in the Prevention of Influenza Virus Infection -

Conditions: Influenza (Prophylaxis) 		CS8958-A-J307
jRCT2080221607
A Phase III Study of CS-8958 (Postexposure Prophylaxis) -A Randomized, Double-blind, Placebo-controlled, Confirmative Study of CS-8958 for Prevention of Influenza-

Conditions: Influenza 		CS8958-A-J306
jRCT2080220909
A Randomized Double-blind Controlled Study of Laninamivir Comparing With Oseltamivir for the Treatment of Influenza in Patients With Chronic Respiratory Diseases

Conditions: Influenza 		CS8958-A-J305
jRCT2080220908
A Phase III Study of CS-8958 -A Randomized Study of CS-8958 Comparing Two Inhalers in Patients With Influenza Virus Infection-

Conditions: Influenza 		CS8958-A-J304
jRCT2080220785
A Phase III Study of CS-8958 - A Randomized Double-blind Comparative Study of CS-8958 in Patients With Influenza Virus Infection Aged 10 to 19 Years -

Conditions: Influenza 		CS8958-A-J303
jRCT2080220784
A Phase II/III Study of CS-8958 in Pediatric Patients -A Randomized Double-blind Controlled Study of CS-8958 Comparing With Oseltamivir Phosphate in Patients With Influenza Virus Infection Aged 9 Years or Younger -

Conditions: Influenza 		CS8958-A-J302
jRCT2080220783
A Randomized Double-blind Controlled Exploratory Study Comparing Repeated Administration of CS-8958 to Oseltamivir Phosphate in Patients With Influenza Virus Infection

Conditions: Influenza 		CS8958-A-J203
jRCT2080220782
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Study for the Evaluation of Efficacy and Safety of CS-8958 in Patients With Influenza Virus Infection

Conditions: Influenza 		CS8958-A-A202
jRCT2080220797
A Randomized Double-blind Controlled Exploratory Study Comparing CS-8958 to Oseltamivir Phosphate in Patients With Influenza Virus Infection (Phase 2)

Conditions: Influenza 		CS8958-A-J201
jRCT2080220781
CS-8958 Clinical Pharmacology Study -Evaluation of Intrapulmonary Pharmacokinetics of CS-8958 and Laninamivir After A Single Inhaled Dose of CS-8958 in Healthy Japanese Subjects-

Conditions: Healthy Participants 		CS8958-A-J108
jRCT2080221402
Clinical Trial of DR-3355 Injection in Patients With Peritonitis

Conditions: Infections 		DR3355-B-J305
jRCT2080221818
Clinical Study of DR-3355 Injection in Patients With Acute Bacterial Prostatitis or Acute Epididymitis

Conditions: Infections 		DR3355-B-J304
jRCT2080221853
Clinical Trial of DR-3355 Injection in Patients With Gynecological Infection

Conditions: Infections 		DR3355-B-J303
jRCT2080221815
Phase III Clinical Study of DR-3355 Injection in Patients With Surgical Infection

Conditions: Infections 		DR3355-B-J302
jRCT2080221802
Comparative Study of DR-3355 Injection and Pazufloxacin Injection in Patients With Urinary Tract Infection

Conditions: Infections 		DR3355-B-J301
jRCT2080221777
An Open-label, Randomized, Active-controlled Study in Patients With Community-acquired Pneumonia

Conditions: Infections 		DR3355-60
jRCT2080220476
Clinical Study of SUN Y7017 (Memantine Hydrochloride) in Combination with Donepezil Hydrochloride in Patients with Moderate to Severe Alzheimer's disease

Conditions: Alzheimer's Disease 		IE3701
jRCT1080221701
Confirmatory Randomized, Duble-blind, Placebo-controlled, Parallel-group Study of SUN Y7017 (Memantine Hydrochloride) in Patients With Mild to Moderate Dementia of the Alzheimer's Type

Conditions: Alzheimer's Disease 		MA3301
jRCT2080220079
Phase III Study of SUN Y7017 (Memantine Hydrochloride) in Patients With Moderately Severe to Severe Dementia of the Alzheimer's Type

Conditions: Alzheimer's Disease 		IE3501
jRCT2080220078
DD-723 Phase III Clinical Trial - Confirmatory Study in Subjects With Suspected Prostate Cancer -

Conditions: Prostate Cancer 		DD723-B-J301
jRCT2080221271
DD-723 Phase II Clinical Trial - Dose-response Study in Patients With Suspected Prostate Cancer -

Conditions: Prostate Cancer 		DD723-B-J201
jRCT2080220862
Phase 3 Clinical Study of DU-6859a in Patients With Respiratory Tract Infection

Conditions: Infections 		DU6859-A-J301
jRCT2080220704
Immunogenicity and Safety of the DTaP-IPV (Sanofi Pasteur Kitasato) Combined Vaccine (DD-687) Given Subcutaneously as a Three-dose Primary and Booster Vaccination Versus Commercially Available DTaP (Kitasato) and Oral Polio Virus (OPV) Vaccines in Infants in Japan

Conditions: Prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis Infection 		DD687-A-J301
jRCT2080221313
Phase II Clinical Study of DD-687 - Single Arm, Unblinded, Uncontrolled Clinical Study in Healthy Japanese Infants -

Conditions: Prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis Infection 		DD687-A-J201
jRCT2080220899
A Phase II, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects With Congestive Heart Failure

Conditions: Congestive Heart Failure/Myocardiopathies 		03-0-162
NCT00259038
Phase III Clinical Study of DQ-2466 -Double-blind Controlled Study of Fixed-dose and Up-titration DQ-2466 Regimens in Subjects With Persistent or Permanent Atrial Fibrillation -

Conditions: Atrial Fibrillation 		DQ2466-A-J301
jRCT2080222155
An Open-label, Multi-center, Phase 2 Study of AMG 162 (denosumab) in Subjects With Giant Cell Tumor of Bone

Conditions: Giant Cell Tumor of Bone 		AMG162-B-J201
jRCT2080221624
Calblock Tablet Postmarketing Clinical Study (Essential Hypertensive Patients With Type 2 Diabetes)

Conditions: Hypertension 		CB502-021
jRCT1080220028
A Phase 1, Randomized, Double Blind, Placebo Controlled, Sequential, Ascending Single-Dose and Multiple-Dose First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC430 in Healthy Subjects

Conditions: Healthy Participants 		AC430-001
NCT01287858
Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Cancer 		AC480IV-001
NCT01245543
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of DS-7011a in Healthy Subjects

Conditions: Healthy Participants 		DS7011-A-U101
NCT05203692
Phase III Clinical Study of DU-176b (Non-valvular Atrial Fibrillation): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Non-valvular Atrial Fibrillation and Severe Renal Impairment

Conditions: Non-valvular Atrial Fibrillation 		DU176b-C-J307
jRCT2080221674
Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

Conditions: Atrial Fibrillation 		DU176b-C-A4012
NCT03247582
Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Thailand)

Conditions: Atrial Fibrillation 		DU176b-C-A4011
NCT03247569
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism (VTE) in Korea and Taiwan (ETNA-VTE-KOR-TWN)

Conditions: Venous Thromboembolism 		DU176b-D-A4010
NCT02952599
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (NVAF) (ETNA-AF-KOR-TWN)

Conditions: Non-Valvular Atrial Fibrillation 		DU176b-C-A4008
NCT02951039
A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

Conditions: Healthy Participants 		DU176b-A-U158
NCT02047565
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Combination With Zetia® Compared to Zetia® Alone in Patients With Primary Hypercholesterolemia

Conditions: Hyper-cholesterolemia 		WEL-408
NCT00185107
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks

Conditions: Hyper-cholesterolemia 		WEL-407
NCT00755352
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks

Conditions: Hyper-cholesterolemia 		WEL-406
NCT00754507
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks

Conditions: Hyper-cholesterolemia 		WEL-405
NCT00753779
The Effects of the Combination of Welchol and Tricor Compared to TriCor Alone in Patients With Mixed Hyperlipidemia

Conditions: Hyper-cholesterolemia/Hyperlipidemia, Familial Combined 		WEL-403
NCT00754039
A Multi-Center, 52-Week, Open-Label Extension Study (From Studies WEL-301, WEL-302, and WEL-303) to Evaluate the Long-Term Safety and Tolerability of WelChol® in Type 2 Diabetic Patients

Conditions: Type 2 Diabetes Mellitus 		WEL-304
NCT00151762
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents

Conditions: Type 2 Diabetes Mellitus 		WEL-303
NCT00147758
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetes With Inadequate Glycemic Control on Insulin Therapy Alone or Insulin Therapy Combination With Other Oral Anti-diabetic Agents

Conditions: Type 2 Diabetes Mellitus 		WEL-302
NCT00151749
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents

Conditions: Type 2 Diabetes Mellitus 		WEL-301
NCT00147719
Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		WEL-202
NCT00361153
An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis

Conditions: Multiple Sclerosis		 CS0777-A-U102
NCT00616733
CS-1036 Phase 2 study - Dose Response Study of CS-1036 in Patients With Type 2 Diabetes -

Conditions: Diabetes 		CS1036-A-J202
jRCT2080221087
CS-1036 Phase 2 Study - Dose Response Study of CS-1036 in Patients With Type 2 Diabetes -

Conditions: Diabetes 		CS1036-A-A201
jRCT2080221036
CS-4771 Phase 1 Study - A Randomized, Double-blind, Placebo-controlled, Continuous IV Infusion for 96 Hours, Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CS-4771 in Japanese Healthy Subjects -

Conditions: Healthy Participants 		CS4771-A-J105
jRCT2080221894
CS-801 Phase 3 Comparative Study

Conditions: Overactive Bladder 		150-010
jRCT2080220025
CS-801 Phase 3 Long-term Study

Conditions: Overactive Bladder 		150-006
jRCT2080220026
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study To Assess The Safety, Pharmacokinetics and Pharmacodynamics Of CS-8080 In Healthy Volunteers

Conditions: Healthy Participants 		CS8080-A-U102
NCT00796575
A Randomized, Placebo-Controlled, Single Ascending Dose Study To Assess The Safety, Tolerability and Pharmacokinetics Of CS-8080 In Healthy Volunteers

Conditions: Healthy Participants 		CS8080-A-U101
NCT00613431
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of CS-917 as Monotherapy for Type 2 Diabetes

Conditions: Type 2 Diabetes Mellitus 		CS0917-A-U205
NCT00290940
Intrathecal Baclofen Therapy With the Implanted Pump System for Spastic Palsy (Post-marketing Clinical Trial Extended Phase 3 After NDA Approval)

Conditions: Spastic Paralysis 		DL404-02P
jRCT1080220031
VN-0103 Ph3 Study -A Randomized, Observer-blind Comparative Study of VN-0103 and Diphtheria-tetanus Toxoid in Japanese Adolescents

Conditions: Prevention of Diphtheria, Tetanus and Pertussis 		VN0103-A-J301
jRCT2080222484
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors Harboring Either a ROS1 or NTRK Fusion Gene

Conditions: Advanced Solid Malignant Tumors 		DS6051-A-J102
NCT02675491
A Phase III, Randomized, Active-comparator, Observer-blind, Non-inferiority Study to Demonstrate the Immunogenicity and Safety of DS-5670d (Monovalent: Omicron XBB.1.5) in Children 5 Through 11 Years of Age

Conditions: Prevention of Infectious Disease by SARS-CoV-2 		DS5670-238
jRCT2031230423
A Phase I, Open Label, Parallel Group Study to Evaluate the Effect of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of a DS 1040b IV Infusion Administered to Healthy Male Subjects

Conditions: Healthy Participants 		DS1040-A-E108
NCT02647307
A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects

Conditions: Healthy Participants 		DS1040-A-E106
NCT02560688
A Phase 1, Open Label, Single Dose Study, to Assess the Safety and Tolerability of A Single IV Dose of DS-1040B After 5 Days of Aspirin Treatment in Healthy Subjects

Conditions: Acute Ischemic Stroke 		DS1040-A-E102
NCT02071004
A Phase 1, First In Human Study of DS-1055a in Subjects With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Conditions: Head and Neck Cancer/Gastric Cancer/Esophageal Cancer/Other Types of Solid Cancer 		DS1055-A-J101
NCT04419532
An Open-Label, Randomised, Parallel Group Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Doses of DS-1093a in Patients With Chronic Kidney Disease

Conditions: Kidney Disease 		DS1093-A-E103
NCT02299661
A Double Blind, Randomised, Placebo-controlled, Multiple Ascending-dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of DS 1093a in Healthy Male Subjects

Conditions: Healthy Participants 		DS1093-A-E102
NCT02142400
Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors

Conditions: Advanced Solid Tumours 		DS1123-A-J101
NCT02690337
Phase I, Single-Blind, Placebo-Controlled, Randomized, Two-Part, Sequential, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		DS1150-A-U101
NCT02004678
DS-7113b Phase I Study -Evaluation of the Safety, Tolerability and Pharmacokinetics of DS-7113b, and the Effect of Food on the Pharmacokinetics of DS-7113b After A Single Dose of DS-7113b (Immediate and Extended Release Formulations) in Healthy Male Japanese Subjects

Conditions: Healthy Participants 		DS7113-A-J102
jRCT2080222121
An Evaluation of Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings

Conditions: Pseudoxanthoma Elasticum 		DS1211-A-U104
NCT05025722
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Type 2 Diabetes Mellitus and Microalbuminuria

Conditions: Type 2 Diabetes Mellitus 		CS3150-B-J204
NCT02345057
Phase 2 Study to Evaluate Safety and Pharmacodynamics of CS-3150 in Type 2 Diabetes Mellitus Patients with Albuminuria

Conditions: Diabetes 		CS3150-B-J202
jRCT2080221972
A Randomized, Double-Blind, Single-Dose, Placebo- and Positive-Controlled Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Exposure to CS-3150 on QTc Interval Duration in Healthy Male and Female Subjects

Conditions: Healthy Participants 		CS3150-A-U106
NCT04019652
Phase 1 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer (CRC) Who Failed First-line Therapy

Conditions: Colorectal Cancer 		CS7017-A-J111
jRCT2080221193
Phase 1 Study of CS-7017 - Evaluation of Safety and Pharmacokinetics of CS-7017 in Japanese Patients With Solid Cancer

Conditions: Solid Cancer 		CS7017-A-J107
jRCT2080220936
A Bioequivalence Study of DS-5565 (Mirogabalin Besilate) - Evaluation of Bioequivalence Between Milogabalin 15 mg Tablet and DS-5565 15 mg Orally Disintegrating (OD) Tablet in Healthy Japanese Subjects -

Conditions: Healthy Participants 		DS5565-A-J316
jRCT1080225061
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Conditions: Diabetic Peripheral Neuropathic Pain 		DS5565-A-A315
NCT04094662
Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond ER (BEAD-MB)

Conditions: Baseline Epidemiologic Assessment 		MORPH-A-U403
NCT04033094
Phase III Clinical Study of SUN Y7017 Double Blind Controlled Study for Safety Evaluation of 1-step Titration With 3-step Titration in Patients With Moderate to Severe Alzheimer's Disease

Conditions: Alzheimer's Disease 		SUNY7017-A-J301
jRCT2080223154
An Open-label, Randomized, 3-period, 3-treatment Crossover Study to Evaluate the Effect of High-fat, High-calorie Food and Standard Food on the Single-dose Pharmacokinetics of Milademetan in Healthy Subjects

Conditions: Healthy Participants 		DS3032-A-U115
NCT03647202
An Open-label, Randomized, 2-period, 2-sequence Study to Evaluate the Single-dose Pharmacokinetics of Milademetan When Administered Alone or Concomitantly With Itraconazole or Posaconazole in Healthy Subjects

Conditions: Healthy Participants 		DS3032-A-U107
NCT03614455
A Randomized Double-Blind Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Conditions: Type 2 Diabetes Mellitus/Neuropathic Pain 		DS1971-A-U202
NCT02673866
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of DS-1971a in Patients With Pain Caused by Radiculopathy Due to Lumbar Spinal Stenosis

Conditions: Pain 		DS1971-A-J201
jRCT2080223138
A Phase I, Double-Blind, Randomised, Placebo Controlled, Multiple-Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971a in Healthy Male and Female Subjects

Conditions: Healthy Participants 		DS1971-A-E106
NCT02564861
A Phase 1, Open-label, Cross-over, Fixed Sequence Study to Evaluate the Effect of Multiple Doses of DS-1971a on the Single Dose Pharmacokinetics of Probe Substrates For CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A4 Enzymes in Healthy Male and Female Subjects

Conditions: Healthy Participants 		DS1971-A-E105
NCT02473627
A Phase 1, Open Label, Randomised, Single Dose, Three Way Crossover Study to Explore the Relative Bioavailability of DS 1971a Given as a 200 mg Tablet Formulation and a 200 mg Oral Suspension, and to Explore the Effects of Administration With a High Fat Meal on the Relative Bioavailability of the Tablet Formulation

Conditions: Healthy Participants 		DS1971-A-E104
NCT02266940
Effects of Age, Gender & Race on the Pharmacokinetics (PK) of DS-1971a

Conditions: Healthy Participants 		DS1971-A-E103
NCT02261376
A Phase I, Double-blind, Randomised, Placebo-controlled, Multiple-dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971s in Healthy Male Subjects

Conditions: Healthy Participants 		DS1971-A-E102
NCT02190058
A Phase 1, Double-blind, Randomized, Placebo-controlled Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971a in Healthy Male Subjects

Conditions: Healthy Participants 		DS1971-A-E101
NCT02107885
A Phase 1, Subject- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Conditions: Netherton Syndrome 		DS2325-106
NCT05583669
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Conditions: Netherton Syndrome 		DS2325-104
NCT05388903
A Phase 1b Study, to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Repeated Doses of DS-2330b Alone and When Co-administered With Sevelamer in Patients on Chronic Hemodialysis

Conditions: Chronic Hemodialysis 		DS2330-A-U103
NCT03305471
DS-2741a Phase I Study- A Three-part First-in-human Study: Single Ascending Dose and Multiple Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-2741a After Subcutaneous Injection in Healthy Japanese Male Subjects, and Single Dose Study to Assess the Pharmacokinetics, Safety, Pharmacodynamics and Efficacy of DS-2741a After Subcutaneous Injection in Japanese Subjects With Moderate to Severe Atopic Dermatitis

Conditions: Atopic Dermatitis/Healthy Participants 		DS2741-A-J101
NCT04211415
A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Conditions: Solid Cancer/Lymphomas 		DS3078-A-U101
NCT01588678
Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients With Advanced Solid Malignant Tumors

Conditions: Advanced Solid Malignant Tumors 		DS5573-A-J101
NCT02192567
Phase I Dose Escalation and Expansion Study of DS-7080a in Subjects With Neovascular Age-related Macular Degeneration or Diabetic Macular Edema

Conditions: Macular Degeneration 		DS7080-A-U101
NCT02530918
DS-7250 -Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Oral Administration in Patients With Type 2 Diabetes-

Conditions: Diabetes 		DS7250-A-J201
jRCT2080221918
A Single Blind, (Subject and Investigator Blinded, Sponsor Unblinded), Two-Period, Placebo-Controlled, Randomized, Sequential, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 In Subjects With Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		DS7309-A-U102
NCT01956305
A Double Blind, Placebo-Controlled, Randomized, Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		DS7309-A-U101
NCT01862939
Phase I Clinical Trial of DS-7423 - Evaluation of Safety and Pharmacokinetics of DS-7423 in Japanese Patients With Advanced Solid Tumors -

Conditions: Solid Cancer 		DS7423-A-J102
jRCT2080221724
A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors

Conditions: Solid Cancer/Colorectal Cancer/Endometrial Cancer 		DS7423-A-U101
NCT01364844
A Phase 1 Study of TRAIL-R2 (DR5) Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Conditions: Advanced Colorectal Cancer 		DS8273-A-U103
NCT02991196
Phase 1, Open-label Study to Assess the Safety and Tolerability of DS-8273a in Subjects WIith Advanced Solid Tumors or Lymphomas

Conditions: Advanced Solid Cancer/Lymphomas 		DS8273-A-U101
NCT02076451
A Phase 2, Randomized, Placebo-controlled, Double-blind, Crossover Study of DS-8500a to Evaluate the Effects on Pancreatic Beta Cell Function in Japanese Patients With Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		DS8500-A-J205
NCT02669732
A Phase 2, Randomized, Double-blind, Placebo-controlled, add-on Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus Receiving Sitagliptin

Conditions: Type 2 Diabetes Mellitus 		DS8500-A-J204
NCT02685345
A Phase 2, Randomized, Double-blind, Dose Finding Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus 		DS8500-A-J203
NCT02628392
A Phase 2, Placebo-controlled, Double-blind Study of DS-8500a in Patients With Type 2 Diabetes

Conditions: Type 2 Diabetes Mellitus 		DS8500-A-J201
NCT02222350
A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects

Conditions: Healthy Participants 		DS8500-A-U112
NCT02790684
An Open-Label, 3-Way Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of DS-8500a in Japanese Healthy Subjects

Conditions: Healthy Participants 		DS8500-A-J110
jRCT2080223244
An Open-Label, One-Sequence, Two-Period Study to Evaluate the Effects of Itraconazole on the Pharmacokinetics of DS-8500a in Healthy Subjects

Conditions: Healthy Participants 		DS8500-A-U109
NCT02790671
A Randomized, Open-label, 3-way Crossover Study to Assess the Pharmacokinetic Drug Interactions Between DS-8500a and A Hypoglycemic Agent (Glimepiride or Repaglinide) in Japanese Healthy Subjects

Conditions: Healthy Participants 		DS8500-A-J108
jRCT2080223178
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of DS-8500a in Japanese Subjects With Varying Degrees of Hepatic or Renal Function

Conditions: Hepatic or Renal Impairment 		DS8500-A-J107
jRCT2080223081
An Open-label, Single-sequence Crossover Study of DS-8500a to Evaluate the Effects on the Pharmacokinetics of Atorvastatin in Japanese Healthy Subjects

Conditions: Healthy Participants 		DS8500-A-J106
jRCT2080222826
An Open-label, Fixed Sequence, Two-period Study to Evaluate the Effects of Repeated Doses of DS-8500a on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

Conditions: Healthy Participants 		DS8500-A-U105
NCT03699774
An Open-label, Non-randomized, Single-sequence Study to Evaluate the Effects of DS-8500a on the Pharmacokinetics of Midazolam in Japanese Healthy Subjects

Conditions: Healthy Participants 		DS8500-A-J104
jRCT2080222622
A Phase 1, Randomized, Placebo-controlled, Double-blind, Multiple Oral Dose Study of DS-8500a in Japanese Healthy Male Subjects

Conditions: Healthy Participants 		DS8500-A-J103
jRCT2080223495
Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects With Advanced Solid Tumors

Conditions: Advanced Solid Cancer 		DS8895-A-J101
NCT02004717
Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (Sub-massive) Acute Pulmonary Embolism (PE)

Conditions: Acute Pulmonary Embolism		 DS9231-A-U201
2017-000552-25
A Multicenter, Prospective, Non-interventional Observational Study to Investigate the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Conditions: Dyslipidemia 		MVT-OS-21-01
NCT05120895
A Multi-center, Prospective Observational Study to Investigate the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

Conditions: Dyslipidemia Associated With Type 2 Diabetes Mellitus 		MVT-OS-15-01
NCT05107063
Affirmation of Primary Prevention With Pravastatin in Reduction of Occlusive Atherosclerotic Complications in Hypercholesterolemia -Japan Study (APPROACH-J)

Conditions: Hyperlipidemia 		APPROACH-J
jRCT1080220524
A Randomized, Double-blind, Stratified, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Heterozygous Familial Hypercholesterolemia and Carotid Atherosclerosis Using Carotid Ultrasound (CUS)

Conditions: Atherosclerosis/Heterozygous Familial Hyper-cholesterolemia 		505-205
NCT00151788
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Coronary Artery Disease Using Intravascular Ultrasound (IVUS)

Conditions: Coronary Artery Disease 		505-202
NCT00185042
Effect of Pactimibe on the Progression of Atherosclerosis as Measured by 2-D and 3-D Carotid Ultrasound

Conditions: Atherosclerosis 		SE-505/14
NCT00185146
Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)

Conditions: Metastatic Breast Cancer 		U31287-A-U202
NCT01512199
Phase 1b Study of Process 2 Patritumab in Combination With Erlotinib in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Conditions: Lung Cancer 		U31287-A-J107
jRCT2080222789
An Open Label, Phase 1B Safety Evaluation of Patritumab (U31287) in Combination With Cetuximab Plus Platinum Containing Therapy In Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Conditions: Head and Neck Cancer 		U31287-A-U106
NCT02350712
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors

Conditions: Solid Tumors 		U31287-A-U105
NCT01957280
Phase 1b Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Patients With HER2-Positive Metastatic Breast cancer (MBC)

Conditions: Breast Cancer 		U31287-A-J103
jRCT2080221730
Phase 1b Study of U3-1287 in Combination With Erlotinib in Subjects With Advanced Aon-small Cell Lung Cancer (NSCLC)

Conditions: Lung Cancer 		U31287-A-J102
jRCT2080221467
Phase 1 Study of U3-1287 -Assessment of the Safety and Pharmacokinetics of U3-1287 in Patients With Advanced Solid Tumors-

Conditions: Solid Cancer 		U31287-A-J101
jRCT2080221225
A Phase II, Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Conditions: Duchenne Muscular Dystrophy 		DS5141-A-J201
NCT04433234
DK-233 (Rifampicin) Bioequivalence Study -Bioequivalence of DK-233 150mg Capsules and DK-233 20 mg/ml Syrup in Healthy Japanese Subjects-

Conditions: Healthy Participants 		RIFADI-A-J101
jRCT1080223619
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Conditions: COPD Exacerbation Acute 		DSCN-GRV AECOPD-CSIS-001
NCT05400369
Multicentre, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Investigate the Efficacy of Sodium Hyaluronate in Patients With Symptomatic Hip Osteoarthritis

Conditions: Hip Osteoarthritis 		ADA 2003-01
NCT00330135
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke

Conditions: Stroke 		ASBI 802
NCT02258880
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis

Conditions: Atopic Dermatitis 		ASBI 404
NCT00717769
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based

Conditions: 		CS1008-A-U105
NCT01124630
Phase 1 Study of CS-1008 - Evaluation of Safety and Pharmacokinetics of CS-1008 in Japanese Patients With Solid Cancer

Conditions: Solid Cancer 		CS1008-A-J104
jRCT2080220861
Phase 1 Study of CS-1008, a Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), Administered Weekly to Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)

Conditions: Solid Cancer/Lymphomas 		CS1008-A-U101
NCT00320827
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3-1565 in Japanese Subjects With Advanced Solid Malignant Tumors

Conditions: Solid Cancer 		U31565-A-J102
jRCT2080221445
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Conditions: Advanced Solid Malignant Tumors/Advanced Ovarian Cancer 		U31565-A-U101
NCT01290471
A Phase 1, Open-label, Two-part, Safety and Tolerability Study of U3-1784 in Patients With Advanced Solid Tumours

Conditions: Advanced Solid Tumors/Hepatocellular Cancer 		U31784-A-E101
NCT02690350
Multi-center Collaborative Research to Investigate the Expression of FGFR2 and HER2 Proteins in Gastric, Gastroesophageal Junction, and Colorectal Cancers

Conditions: Gastric Cancer/Gastroesophageal Junction Cancer/Colorectal Cancer 		DS-Screen
jRCT1080223325
A Non-interventional Study to Assess Lung Function in Japanese Children and Elderly

Conditions: Healthy Participants (Measure of Tidal Breathing) 		N/A
jRCT1080223039
A Randomized, Double-Blind, Placebo-Controlled, Dose and Active Comparator-Controlled Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes

Conditions: Type 2 Diabetes Mellitus 		CS011-A-J205
NCT00575874
A Randomized, Double-Blind, Placebo-Controlled 12-Week Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes

Conditions: Type 2 Diabetes Mellitus 		CS011-A-J204
NCT00575471
A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes

Conditions: Type 2 Diabetes Mellitus 		CS0011-203
NCT00143520
Phase III Study of SUN11031 for Eating Disorders

Conditions: Anorexia 		SUN11031
jRCT2080220697
A Phase 1, Open-Label Study Assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors

Conditions: Solid Cancer/Hepatic Impairment 		ARQ197-A-U160
NCT02150733
A Phase 1 Single-blind, Single-sequence Study Assessing the Effect of Tivantinib on the QTC Interval in Cancer Subjects

Conditions: Cancer 		ARQ197-A-U159
NCT01699061
A Phase 1, Open-Label, Single-Sequence Crossover Study Assessing the Effect of Tivantinib (ARQ 197) on the Pharmacokinetics of Omeprazole/S-Warfarin/Caffeine/Midazolam and Digoxin in Cancer Subjects

Conditions: Solid Tumors 		ARQ197-A-U158
NCT01517399
An Open-Label, Phase 1, Randomized, Two-Treatment, Two-Period, Two-Way Crossover, Relative Bioavailability Study Of A Capsule And A Tablet Formulation Of ARQ 197 In Subjects With Advanced Solid Tumors

Conditions: Solid Tumors 		ARQ197-A-U157
NCT01149720
A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors

Conditions: Small Cell Lung Cancer/Non-small Cell Lung Cancer/Cervical Cancer/Ovarian Cancer/Gastric Cancer 		TOP009-062
NCT01040312
A Prospective Observational Study of the Efficacy and Safety of CPT-11 Based Regimens for UGT1A1 Genotype Guided Patients With Metastatic Colorectal Cancer

Conditions: Colorectal Cancer 		TOP009-061
NCT01039506
A Randomized Phase III Trial of S-1 Versus S-1 Plus Irinotecan in Advanced Gastric Cancer

Conditions: Gastric Cancer 		TOP-002
jRCT1080220081
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer

Conditions: Colorectal Cancer 		TOP-003
NCT00284258
A Phase 2, Double-blind, Randomized, Safety and Efficacy Study of GE-145 Versus Iodixanol in Subjects Undergoing Cerebral Angiography

Conditions: Coronary Angiography 		GE145-A-J203
jRCT2080222467
A Phase 2, Double-blind, Randomized, Safety and Efficacy Study of GE-145 Versus Iodixanol in Subjects Undergoing Peripheral Angiography

Conditions: Peripheral Angiography 		GE145-A-J202
jRCT2080222468
A Phase 2, Double-blind, Randomized, Safety and Efficacy Study of GE-145 Versus Iohexol in Subjects Undergoing Coronary Angiography

Conditions: Coronary Angiography 		GE145-A-J201
jRCT2080222341
A Randomized, Double-Blind, Placebo-controlled Phase III Study of DE-766 with Cisplatin/Vinorellbine plus Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Squamous Cell Lung Cancer

Conditions: Lung Cancer 		DE766-A-J303
jRCT2080222038
A Phase II Study of Nimotuzumab in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer 		DE766-A-J202
jRCT2080220796
Japan/Korea Joint Phase II Study of Nimotuzumab Plus Irinotecan in Patients With Advanced or Recurrent Gastric Cancer

Conditions: Gastric Cancer 		DE766-A-J201
jRCT2080220818
A Phase I Study of DE-766 With Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer

Conditions: Esophageal Cancer 		DE766-A-J102
jRCT2080221282
A Pilot, Multicenter, Open Label, Non Comparative Study of the Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media Twice Daily for Seven Days in Children With Tympanostomy Tubes

Conditions: Infections 		8280A-PRT021
NCT00781521
Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study

Conditions: Essential Hypertension/Carotid Plaque 		DSE-OLM-01-09
NCT01132768
Efficacy of Sevikar® Compared to the Combination of Perindopril/Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension

Conditions: Hypertension 		DSE-SEV-02-09
NCT01101009
Olmesartan Mega study to determine the relationship between Cardiovascular Endpoints and Blood pressure Goal Achievement (OMEGA)

Conditions: Hypertension 		OMEGA study
jRCT1080220002
An Open Label, Non-comparative Observational Study to Evaluate the Efficacy and Safety of Olmesartan Medoxomil Tablet 20mg in the Treatment of Mild to Moderate Essential Hypertension for 24 Weeks in Chinese Patients & a Sub-group of ABPM Study to Measure the T/P Ratio and Ambulatory Blood Pressure Change

Conditions: Hypertension 		PMS-OLM-200801
jRCT1080221127
Open-label, Phase III Study of CS-866AZ

Conditions: Hypertension 		CS0866AZ-A-J303
jRCT2080220439
Add-on, Open-label, Phase III Study of CS-866AZ

Conditions: Hypertension 		CS0866AZ-A-J302
jRCT2080220290
A Randomized-controlled, Double-blinded, Phase III Study of CS-866AZ

Conditions: Hypertension 		CS0866AZ-A-J301
jRCT2080220281
A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension

Conditions: Hypertension 		866-447
NCT00185120
Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment

Conditions: Essential Hypertension/Renal Impairment 		SE-866/43
NCT00151827
A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

Conditions: Essential Hypertension 		SS-866/01
NCT00856271
A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension, Who Fail to Attain the Blood Pressure Goals With Olmesartan Medoxomil 20mg Monotherapy

Conditions: Essential Hypertension 		SS-866 CMB/01
NCT00872586
An Open-label Study of Olmesartan Medoxomil (CS-866) in Normotensive Patients With Chronic Glomerulonephritis or Diabetic Nephropathy

Conditions: Chronic Glomerulonephritis/Diabetic Nephropathy 		CS0866-C-J201
NCT00914524
Vascular Improvement With Olmesartan Medoxomil Study (VIOS)

Conditions: Hypertension 		866-432
NCT00772499
Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension

Conditions: Isolated Systolic Hypertension 		SE-866/37
NCT00751829
Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension

Conditions: Essential Hypertension 		SE-866/36
NCT00751751
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Conditions: Atherosclerosis 		866-422 AIMS
NCT00382213
Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy

Conditions: Type 2 Diabetes Mellitus/Renal Disease 		SE-866/29
NCT00362960
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)

Conditions: Atherosclerosis/Essential Hypertension 		SE-866/27
NCT00185185
The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects

Conditions: Healthy Participants 		866-448
NCT00185055
A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar® HCT in Patients With Stage II Systolic Hypertension

Conditions: Essential Hypertension 		866-443
NCT00185068
The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension

Conditions: Essential Hypertension 		866-440
NCT00185094
Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension

Conditions: Essential Hypertension 		SP-OLM-01-00
NCT00185172
A Randomized, Double-blind, Placebo-controlled Factorial Study Evaluating the Efficacy and Safety of Co-administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension

Conditions: Hypertension 		CS8663-A-U301
NCT00185133
Pharmacokinetic Study of Olmesartan Medoxomil/Amlodipine 20/5 mg Tablet in Chinese Healthy Adult Volunteers

Conditions: Healthy Participants 		SS8663-03
jRCT2080221540
A Randomized, Double-blind, Double-dummy, Parallel Group, Active Controlled Multi-center Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil/Amlodipine 20/5 mg in Chinese Patients With Mild or Moderate Essential Hypertension Who Failed to Achieve Their Goal With Amlodipine 5mg Monotherapy

Conditions: Hypertension 		SS8663-02
jRCT2080221541
A Randomized, Double-blind, Double-dummy, Parallel Group, Active Controlled Multi-center Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil/Amlodipine 20/5 mg in Chinese Patients With Mild or Moderate Essential Hypertension Who Failed to Achieve Their Goal With Olmesartan Medoxomil 20mg Monotherapy

Conditions: Hypertension 		SS8663-01
jRCT2080221543
A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With Dual Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg

Conditions: Essential Hypertension 		CS8635-SIT-11-01
NCT01838850
CS-747S Phase III Trial -Double-blinded Study for Evaluation of Efficacy and Safety of CS-747S in Reference to Clopidogrel Bisulfate in Subject With Coronary Arterial Disease Who Are to Undergo Elective Percutaneous Coronary Intervention-

Conditions: Coronary Artery Disease 		CS0747S-B-J302
jRCT2080221511
CS-747S Phase III Trial -Double-blinded Comparative Study for Evaluation of Efficacy and Safety of CS-747S Versus Clopidogrel Bisulfate in Subject With Acute Coronary Syndromes Who Are to Undergo Percutaneous Coronary Intervention-

Conditions: Acute Coronary Syndrome 		CS0747S-B-J301
jRCT2080221302
DD-723 Phase III Clinical Trial - Confirmatory Study in Subjects With Breast Tumor -

Conditions: Breast Cancer 		DD723-B-J302
jRCT2080221250
DD-723 Phase II Clinical Trial - Dose-response Study in Patients With Breast Tumor -

Conditions: Breast Cancer 		DD723-B-J202
jRCT2080220863
A Phase II Study Of Oral DJ-927 Administered As A Single Dose Every Three Weeks To Patients With Advanced Or Metastatic Adenocarcinoma Of The Colon Or Rectum

Conditions: Colorectal Cancer 		CDR0000356034
NCT00080834
A Phase I Study Of The Combination of Oral DJ-927 And Capecitabine In Patients With Advanced Solid Tumors

Conditions: Solid Cancer 		CDR0000346368
NCT00077077
A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy

Conditions: Soft Tissue Sarcoma 		CDR0000310138
NCT00064220
A Phase II Study Of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, To Patients With Progressive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) Following Treatment With Platinum-Based Chemotherapy

Conditions: Non-small Cell Lung Cancer 		CDR0000301749
NCT00061854
A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT)

Conditions: Sarcoma 		CDR0000271889
NCT00055952
A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma

Conditions: Sarcoma 		CDR0000271888
NCT00055939
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region

Conditions: Xerostomia		 CDR0000068698
NCT00017511
A Randomized, Open-Label, Multicenter Phase III Study Comparing the Efficacy and Safety of a Combination of Intravenous DX-8951f (Exatecan Mesylate) Plus Gemcitabine to Gemcitabine Alone in Patients With Locally Advanced or Metastatic Cancer of the Exocrine Pancreas Who Have Not Received Prior Chemotherapy

Conditions: Pancreatic Cancer 		CDR0000068880
NCT00023972
A Phase II Study Of Intravenous Exatecan Mesylate (DX-891F) Administered Daily For Five Days Every Three Weeks To Patients With Previously Untreated Metastatic Gastric Cancer

Conditions: Esophageal Cancer/Gastric Cancer 		CDR0000068663
NCT00017212
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Conditions: Biliary Cancer 		CDR0000067736
NCT00005938
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix

Conditions: Cervical Cancer 		CDR0000067525
NCT00004866
A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas

Conditions: Brain and Central Nervous System Cancer/Lymphoma/Unspecified Childhood Solid Cancer 		CDR0000067330
NCT00004212
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hepatocellular Carcinoma

Conditions: Liver Cancer 		CDR0000067329
NCT00004108
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane and Topotecan

Conditions: Ovarian Cancer/Fallopian Tube Cancer/Peritoneal Cancer 		CDR0000067258
NCT00004060
A Phase I Study of Intravenous DX-8951f in Patients With Advanced Myelodysplastic Syndromes, Refractory Acute Leukemia, Refractory or Transformed Chronic Lymphocytic Leukemia, and Chronic Myelogenous Leukemia in Blastic Phase

Conditions: Hematologic Cancer 		CDR0000067149
NCT00004047
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Adenocarcinoma of the Breast

Conditions: Breast Cancer 		CDR0000067148
NCT00004046
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Carcinoma of the Pancreas

Conditions: Pancreatic Cancer 		CDR0000067147
NCT00003951
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hormone-Refractory Prostate Cancer

Conditions: Prostate Cancer 		CDR0000067146
NCT00004045